
<html lang="en"     class="pb-page"  data-request-id="b8e714fd-f83a-45cb-9b5b-add9ea09d5cd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00106;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-8;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)" /></meta><meta name="dc.Creator" content="Chih-Hsiang  Tu" /></meta><meta name="dc.Creator" content="Wen-Hsing  Lin" /></meta><meta name="dc.Creator" content="Yi-Hui  Peng" /></meta><meta name="dc.Creator" content="Tsu  Hsu" /></meta><meta name="dc.Creator" content="Jian-Sung  Wu" /></meta><meta name="dc.Creator" content="Chun-Yu  Chang" /></meta><meta name="dc.Creator" content="Cheng-Tai  Lu" /></meta><meta name="dc.Creator" content="Ping-Chiang  Lyu" /></meta><meta name="dc.Creator" content="Chuan  Shih" /></meta><meta name="dc.Creator" content="Weir-Torn  Jiaang" /></meta><meta name="dc.Creator" content="Su-Ying  Wu" /></meta><meta name="dc.Description" content="Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available. Herein, we present the structure of ALK in complex with ..." /></meta><meta name="Description" content="Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available. Herein, we present the structure of ALK in complex with ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 12, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00106" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00106" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00106" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00106" /></link>
        
    
    

<title>Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00106" /></meta><meta property="og:title" content="Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0011.jpeg" /></meta><meta property="og:description" content="Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available. Herein, we present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type II binding mode. It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK. A structure–activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK. To the best of our knowledge, this is the first structural biology study to directly observe how changes in the structure of a small molecule can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00106"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00106">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00106&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00106&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00106&amp;href=/doi/10.1021/acs.jmedchem.6b00106" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3906-3919</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00087" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00134" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chih-Hsiang++Tu">Chih-Hsiang Tu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wen-Hsing++Lin">Wen-Hsing Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Hui++Peng">Yi-Hui Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tsu++Hsu">Tsu Hsu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian-Sung++Wu">Jian-Sung Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Yu++Chang">Chun-Yu Chang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng-Tai++Lu">Cheng-Tai Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ping-Chiang++Lyu">Ping-Chiang Lyu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chuan++Shih">Chuan Shih</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weir-Torn++Jiaang">Weir-Torn Jiaang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Su-Ying++Wu">Su-Ying Wu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Institute of Bioinformatics and Structural Biology, National Tsing Hua University, 101, Sect. 2, Guangfu Road, Hsinchu 300, Taiwan, ROC</span></div><div class="corresp-info"><strong>*</strong>W.-T.J.: phone, +886-37-246-166, extension 35712; fax, +886-37-586-456; e-mail, <a href="/cdn-cgi/l/email-protection#addad9c7c4ccccc3caedc3c5dfc483c2dfca83d9da"><span class="__cf_email__" data-cfemail="b9cecdd3d0d8d8d7def9d7d1cbd097d6cbde97cdce">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>S.-Y.W.: phone, +886-37-246-166, extension 35713; fax, +886-37-586-456; e-mail, <a href="/cdn-cgi/l/email-protection#394a4c4050575e7957514b5017564b5e174d4e"><span class="__cf_email__" data-cfemail="3a494f4353545d7a545248531455485d144e4d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00106&amp;href=/doi/10.1021%2Facs.jmedchem.6b00106" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3906–3919</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 31, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 January 2016</li><li><span class="item_label"><b>Published</b> online</span>12 April 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 April 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00106" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00106</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3906%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChih-Hsiang%2BTu%252C%2BWen-Hsing%2BLin%252C%2BYi-Hui%2BPeng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D8%26contentID%3Dacs.jmedchem.6b00106%26title%3DPyrazolylamine%2BDerivatives%2BReveal%2Bthe%2BConformational%2BSwitching%2Bbetween%2BType%2BI%2Band%2BType%2BII%2BBinding%2BModes%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3919%26publicationDate%3DApril%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00106"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1466</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00106" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chih-Hsiang&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Wen-Hsing&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Yi-Hui&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Tsu&quot;,&quot;last_name&quot;:&quot;Hsu&quot;},{&quot;first_name&quot;:&quot;Jian-Sung&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Chun-Yu&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Cheng-Tai&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Ping-Chiang&quot;,&quot;last_name&quot;:&quot;Lyu&quot;},{&quot;first_name&quot;:&quot;Chuan&quot;,&quot;last_name&quot;:&quot;Shih&quot;},{&quot;first_name&quot;:&quot;Weir-Torn&quot;,&quot;last_name&quot;:&quot;Jiaang&quot;},{&quot;first_name&quot;:&quot;Su-Ying&quot;,&quot;last_name&quot;:&quot;Wu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;3906-3919&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00106&quot;},&quot;abstract&quot;:&quot;Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available. Herein, we present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type II binding mode. It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK. A structure–activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK. To the best of our knowledge, this is the first structural biology study to directly observe how changes in the structure of a small molecule can regulate the switch between the type I and type II bi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00106&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00106" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00106&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00106" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00106&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00106" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00106&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00106&amp;href=/doi/10.1021/acs.jmedchem.6b00106" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00106" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00106" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00106%26sid%3Dliteratum%253Aachs%26pmid%3D27031565%26genre%3Darticle%26aulast%3DTu%26date%3D2016%26atitle%3DPyrazolylamine%2BDerivatives%2BReveal%2Bthe%2BConformational%2BSwitching%2Bbetween%2BType%2BI%2Band%2BType%2BII%2BBinding%2BModes%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D8%26spage%3D3906%26epage%3D3919%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a>,</li><li><a href="/action/doSearch?ConceptID=292538" title="Conformational transitions">Conformational transitions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/jmcmar.2016.59.issue-8/20160428/jmcmar.2016.59.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type I binding mode, but only limited type II ALK structural studies are available. Herein, we present the structure of ALK in complex with <i>N</i>1-(3-4-[([5-(<i>tert</i>-butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1<i>H</i>-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (<b>5a</b>), a novel ALK inhibitor adopting a type II binding mode. It revealed binding of <b>5a</b> resulted in the conformational change and reposition of the activation loop, αC-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK. A structure–activity relationship study revealed that modifications to the structure of <b>5a</b> led to significant differences in the ALK potency and altered the protein structure of ALK. To the best of our knowledge, this is the first structural biology study to directly observe how changes in the structure of a small molecule can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23531" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23531" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK) was first discovered as the nucleophosmin (NPM)-ALK fusion protein in the anaplastic large cell lymphoma (ALCL) of non-Hodgkin’s lymphoma (NHL) patients in 1994.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is classified as a receptor tyrosine kinase (RTK) and consists of an extracellular ligand binding domain, a transmembrane domain, a juxtamembrane domain, an intracellular kinase domain, and a C-terminal tail.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Midkine (MK) and pleiotrophin (PTN), two neurite growth-promoting factors (NEGF), have been reported as the activating ligands for mammalian ALK.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Since the first discovery of NPM-ALK in NHL patients, various ALK-fused partners have been identified, including cysteinyl-tRNA synthetase (CARS)-ALK in inflammatory myofibroblastic tumors (IMT); clathrin (CLTC)-ALK in diffuse large B-cell lymphoma (DLBCL); and echinoderm microtubule associated protein like 4 (EML4)-ALK in non-small-cell lung carcinoma (NSCLC).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Among these, EML4-ALK, identified in about 3–7% of NSCLC patients,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> is one of the most extensively studied ALK fusions. The N-terminal portion of EML4 facilitates ALK oligomerization, kinase activation and subsequently initiates the signal transduction network. Studies have shown that mutations, gene amplification, and chromosomal translocation of ALK are associated with various cancers.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Therefore, ALK has been proposed as a drug target in the treatment of tumors, and the inhibition of ALK by small molecules constitutes a promising approach due to the low ALK mRNA and protein expression levels in normal human tissue.<a onclick="showRef(event, 'ref2 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref5">(2, 5)</a> Currently, several ALK inhibitors, including crizotinib,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> ceritinib,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and alectinib,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> are FDA-approved for the treatment of ALK positive NSCLC patients and several second-generation inhibitors such as <i>N</i>2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-<i>N</i>4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine (ASP3016),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> 5-chloro-<i>N</i>2-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-<i>N</i>4-[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine (AP26113),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and (10<i>R</i>)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2<i>H</i>-8,4-(metheno)pyrazolo[4,3-<i>h</i>][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922)<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> are in clinical trials. Unfortunately, some of these are associated with adverse effects. For example, nausea, vomiting, diarrhea, visual disorders, and peripheral edema were observed in patients after receiving crizotinib treatment.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Ceritinib produced adverse effects; nausea, diarrhea, vomiting, and fatigue were observed in clinical trials.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The reported side effects of alectinib were dysgeusia, anemia, elevated aminotransferase levels, rash, and constipation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Hence, further development of ALK inhibitors for the treatment of cancer is needed.</div><div class="NLM_p">Type I kinase inhibitors are ATP competitors and target the DFG-in kinase conformation, whereas type II kinase inhibitors recognize the DFG-out conformation.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In addition, type II kinase inhibitors not only occupy the ATP binding site but also exploit the less conserved allosteric pocket by flipping the DFG motif, which might improve kinase selectivity and reduce the potential for resistance.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> Moreover, type II kinase inhibitors generally display a lower dissociation rate constant (<i>k</i><sub>off</sub>) with prolonged residence time, which would extend the efficacy both in vitro and in vivo.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> However, most type II inhibitors tend to have high molecular weight and lipophilicity in order to exploit the additional hydrophobic pocket. In consequence, the majority of type II inhibitors have the potential problems of limited solubility and worse pharmacokinetic (PK) properties.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> These require further efforts in the late stage of drug development to improve the druggability of type II inhibitors.</div><div class="NLM_p">Nevertheless, the use of type II kinase inhibitors, such as imatinib,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> has been viewed as beneficial approach for the treatment of cancers. Unfortunately, due to the limitations of the traditional enzymatic assay, few type II ALK kinase inhibitors have been identified.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> In addition, limited DFG-out ALK/inhibitor structures available for structure-guided in drug design may impede the effort on the design and optimization of type II ALK inhibitors.</div><div class="NLM_p last">In this study, a screening of in-house kinases led to the identification of <b>5a</b>, a 3-phenyl-1<i>H</i>-5-pyrazolylamine-based compound bearing a urea substituent, as an ALK inhibitor with an IC<sub>50</sub> value of 177 nM. Herein, we describe structural biology studies of <b>5a</b> with ALK, revealing it to adopt a type II binding mode and concurrently rearrange the conformations of the activation loop, αC-helix, and juxtamembrane domain. Upon binding to ALK, compound <b>5a</b> induces movement of the αC-helix which allosterically regulates the autoinhibition state of the juxtamembrane domain from antiparallel β-sheets to a less compact, short helix conformation. A subsequent structure–activity relationship (SAR) study revealed that modifications to the structure of <b>5a</b> led to a significant difference in the ALK inhibitor potency. Moreover, comparison of the cocrystal structure of ALK in complex with <b>5a</b> with that of its analogue, <b>4</b>, demonstrated that modification of inhibitor structure could switch it between a type I and type II binding mode and induce dramatic conformational changes.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Identification of Pyrazolylamine Derivatives as ALK Inhibitors</h3><div class="NLM_p">A novel class of 3-phenyl-1<i>H</i>-5-pyrazolylamine derivatives<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> has been utilized as a versatile template for the development of kinase inhibitors. Further screening of this series of compounds against in-house kinases led to the identification of urea-substituted series of compounds as ALK inhibitors. As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, <b>5a</b> was the most potent ALK inhibitor, with an IC<sub>50</sub> value of 177 nM. The general synthetic route to 3-phenyl-1<i>H</i>-5-pyrazolylamine benzamides, <b>5a</b> and its analogs (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Structure–activity relationship (SAR) studies showed that modifications to the urea-substituted tail moiety (R<sup>1</sup> group in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) could significantly affect ALK potency. Removing the urea-substituted moiety of <b>5a</b> to give <b>4</b> resulted in the complete loss of activity (IC<sub>50</sub> > 10 μM), suggesting the urea-substituted moiety to be very important for the inhibition of ALK. Replacement of the isoxazole ring of <b>5a</b> with a phenyl ring to give <b>5b</b> decreased the activity to IC<sub>50</sub> = 6.2 μM. Adding a methyl group next to the urea moiety to give <b>5c</b> also reduced the activity (IC<sub>50</sub> = 4.5 μM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. ALK Inhibition of <b>5a</b> and Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values are expressed as the mean of at least three independent experiments and are within ±15%.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">LE= −1.4 log(IC<sub>50</sub>)/HAC.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> HAC is the number of non-hydrogen atoms of the ligand.</p></div></div><div></div></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) pyridine, rt, (ii) H<sub>2</sub>, Pd/C, MeOH/HCl (aq); (b) pyridine, phenyl isocyanate or (5-alkylisoxazol-3-yl)carbamic acid 4-nitrophenyl ester, rt.</p></p></figure><div class="NLM_p">The effect of alkyl substituents on the terminal isoxazole ring on ALK inhibition was also evaluated. In comparison with the bulky <i>tert</i>-butyl group of <b>5a</b>, compounds bearing the less sterically hindered isopropyl group (<b>5d</b>), ethyl group (<b>5e</b>), and methyl group (<b>5f</b>) were synthesized and tested, and the substitution was found to result in a 2-fold, 4-fold, and 32-fold decrease in potency, respectively. Removal of the methyl substituent (R<sup>2</sup> group in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) on the phenyl ring connected to the pyrazolylamine group to give <b>5g</b> and <b>5h</b> resulted in decreased ALK inhibition compared with their methyl analogues, <b>5a</b> and <b>5d</b>.</div><div class="NLM_p last">The effect of adding a water-solubilizing group on ALK inhibition was investigated. Previous studies have demonstrated the importance of a water-solubilizing substituent on the benzamide moiety for optimal activity toward the FLT3 kinase.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23-25)</a> In this study, addition of various water-solubilizing benzamide substituents to the urea substituted moiety had dramatic effects on potency. With conservation of the 5-<i>tert</i>-butylisoxazoleurea moiety, inhibitors bearing a pyrrolidine group tethered by either a two-carbon (<b>5i</b>) or three-carbon ether (<b>5j</b>) were found to be 3-fold and 7-fold less potent than a <i>N</i>-methylpiperazine group linked by a one-carbon tether (<b>5a</b>). A sharp drop in potency was observed when the pyrrolidine group (<b>5i</b>) was replaced by a morpholine group (<b>5k</b>) or an <i>N</i>-methylpiperazine group was directly attached to benzamide (<b>5l</b>). Both compounds <b>5k</b> and <b>5l</b> showed no inhibition (IC<sub>50</sub> > 10 μM).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Crystal Structure of <b>5a</b></h3><div class="NLM_p">To further elucidate the binding mode and get structural insights into the detailed interactions between compound <b>5a</b> and ALK, a structural biology study of <b>5a</b> in complex with the ALK kinase domain (amino acids 1084–1410) was performed. Compound <b>5a</b> was soaked into the ALK native crystal and the structure of <b>5a</b> bound to ALK determined to a resolution of 1.92 Å. Data collection and refinement statistics are summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. All the protein residues were well-defined in the electron density map except for some flexible loops, including residues 1084–1092, 1124–1127, 1137–1143, 1216–1219, 1275–1287, and 1405–1410.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure Data Collection and Structure Refinement Statistics of ALK Complex Structure</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">apo ALK</th><th class="colsep0 rowsep0" align="center">ALK/<b>5a</b></th><th class="colsep0 rowsep0" align="center">ALK/<b>4</b></th><th class="colsep0 rowsep0" align="center">ALK/<b>5d</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution range (Å)</td><td class="colsep0 rowsep0" align="left">19.69–1.5</td><td class="colsep0 rowsep0" align="left">29.29–1.92</td><td class="colsep0 rowsep0" align="left">23.63–1.87</td><td class="colsep0 rowsep0" align="left">19.53–2.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unit cell (α = β = γ = 90°)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i> (Å)</td><td class="colsep0 rowsep0" align="left">51.768</td><td class="colsep0 rowsep0" align="left">51.913</td><td class="colsep0 rowsep0" align="left">51.851</td><td class="colsep0 rowsep0" align="left">52.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>b</i> (Å)</td><td class="colsep0 rowsep0" align="left">57.999</td><td class="colsep0 rowsep0" align="left">56.495</td><td class="colsep0 rowsep0" align="left">57.432</td><td class="colsep0 rowsep0" align="left">56.575</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>c</i> (Å)</td><td class="colsep0 rowsep0" align="left">104.691</td><td class="colsep0 rowsep0" align="left">102.710</td><td class="colsep0 rowsep0" align="left">105.017</td><td class="colsep0 rowsep0" align="left">103.049</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unique reflections</td><td class="colsep0 rowsep0" align="left">50680 (4931)</td><td class="colsep0 rowsep0" align="left">23336 (2256)</td><td class="colsep0 rowsep0" align="left">25768 (2543)</td><td class="colsep0 rowsep0" align="left">17835 (1618)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%) (outer shell)</td><td class="colsep0 rowsep0" align="left">99.17 (97.92)</td><td class="colsep0 rowsep0" align="left">99.31 (98.47)</td><td class="colsep0 rowsep0" align="left">97.93 (98.07)</td><td class="colsep0 rowsep0" align="left">96.10 (90.29)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mean <i>I</i>/σ(<i>I</i>)</td><td class="colsep0 rowsep0" align="left">16.08 (2.92)</td><td class="colsep0 rowsep0" align="left">15.82 (3.62)</td><td class="colsep0 rowsep0" align="left">12.50 (3.04)</td><td class="colsep0 rowsep0" align="left">15.66 (3.81)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Wilson <i>B</i>-factor</td><td class="colsep0 rowsep0" align="left">19.74</td><td class="colsep0 rowsep0" align="left">23.91</td><td class="colsep0 rowsep0" align="left">23.45</td><td class="colsep0 rowsep0" align="left">28.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>work</sub>/<i>R</i><sub>free</sub> (%)</td><td class="colsep0 rowsep0" align="left">18.18/20.07</td><td class="colsep0 rowsep0" align="left">18.29/21.12</td><td class="colsep0 rowsep0" align="left">17.94/20.51</td><td class="colsep0 rowsep0" align="left">18.11/22.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rmsd (bonds) (Å)</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">0.007</td><td class="colsep0 rowsep0" align="left">0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rmsd (angles) (deg)</td><td class="colsep0 rowsep0" align="left">0.96</td><td class="colsep0 rowsep0" align="left">0.93</td><td class="colsep0 rowsep0" align="left">1.07</td><td class="colsep0 rowsep0" align="left">0.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran favored (%)</td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MolProbity clash score</td><td class="colsep0 rowsep0" align="left">1.49</td><td class="colsep0 rowsep0" align="left">0.45</td><td class="colsep0 rowsep0" align="left">2.33</td><td class="colsep0 rowsep0" align="left">1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MolProbity score</td><td class="colsep0 rowsep0" align="left">0.89</td><td class="colsep0 rowsep0" align="left">0.77</td><td class="colsep0 rowsep0" align="left">1.19</td><td class="colsep0 rowsep0" align="left">0.89</td></tr></tbody></table></div></div><div class="NLM_p">The structural moieties of ALK in complex with <b>5a</b> were the following: the small N-terminal lobe (N-lobe); the large C-terminal lobe (C-lobe); and the interconnection hinge region. The N-lobe comprises five antiparallel β-sheets and one dominant helix (αC-helix). The C-lobe comprises predominantly eight α-helices and an activation-loop (A-loop). The electron density map clearly shows that <b>5a</b> is located in the ATP binding site between the N-lobe and C-lobe. Unlike most known ALK inhibitors (which present as type I inhibitors), <b>5a</b> adopts the type II inhibitor binding mode and exploits the additional hydrophobic pocket, created by the rearrangement of the activation loop of ALK from the DFG-in to the DFG-out conformation. Indeed, <b>5a</b> bears several structural features that bind to ALK: the hinge scaffold (pyrazolylamine), the water-solubilizing headgroup (<i>N</i>-methylpiperazine), the middle linker (tolyl), hydrogen-bonding moiety (urea), and hydrophobic tail group (<i>tert</i>-butylisoxazole) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A). The pyrazolylamine scaffold of <b>5a</b> forms hydrogen bonds with Glu1197 and Met1199 in the hinge region (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B), stabilizing the binding orientation and coordinating 5-<i>tert</i>-butylisoxazole group deeply into the hydrophobic pocket. The tolyl group at the 3-position next to the pyrazolylamine scaffold makes hydrophobic interactions with the surrounding residues, including Val1130, Leu1196, Leu1256, and Phe1271. Moreover, the rearrangement of the side chain of Phe1271 of DFG motif provides the edge-to-face hydrophobic interactions with the tolyl group. The methyl substituent in the tolyl group has interactions with Phe1271 and also contributes to the inhibitory activity to ALK. Removal of this methyl substitute results in 5-fold decreased activity of <b>5g</b> as compared with <b>5a</b>. The <i>N</i>-methylpiperazine headgroup is located at the acidic zone, formed by the side chains of Asp1203, Ser1206, and Glu1210 and the backbone carbonyl oxygens of Ala1200 and Gly1201 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B). The methylpiperazine group is a water-solubilizing group, often used in kinase inhibitor design to improve the physicochemical properties of compounds.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> However, the methylpiperazine group not only improved the physicochemical properties of <b>5a</b> but also significantly influences potency against ALK, as revealed in the aforementioned SAR study. The two tertiary amines of the <i>N</i>-methylpiperazine of <b>5a</b> serve as bases to form the long range charge–charge interactions with the carboxylic acid group of Glu1210 and the backbone carbonyl oxygens of Ala1200 and Gly1201. With an increase (<b>5k)</b> or decrease (<b>5l)</b> in chain length, the inhibitory activities decrease. One reason for the dramatic loss of activity of <b>5k</b> could be that the water-solubilizing group is away from the acidic region, which leads to the loss of charge–charge interactions with the surrounding residues. Another possibility is that the basicity of the water-solubilizing group might also contribute to the binding with the protein. The p<i>K</i><sub>a</sub> of the nitrogen atom in the morpholine-4-ylmethoxy group of <b>5k</b> is 4.09, while p<i>K</i><sub>a</sub> values of two nitrogen atoms in <i>N</i>-methylpiperazine of <b>5a</b> are 7.84 and 8.07 as calculated by MarvinSketch program implemented in ChemAxon.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The nitrogen atom in the morpholine-4-yl-methoxy group with the lower p<i>K</i><sub>a</sub> value and less basicity might have weaker charge interactions with the acidic residues of ALK, resulting in a loss in activities. Moreover, the reason for the decreased activity of <b>5l</b> could be that the shorter chain length restricted the orientation of <i>N</i>-methylpiperazine to form optimized interactions with the surrounding acidic residues.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Pharmacophore of <b>5a</b>, the type II ALK inhibitor. <b>5a</b> was divided into five different portions, including the water-exposed headgroup (yellow), hinge binding group (cyan), aromatic linker (green), hydrogen bonding motif (purple), and tail group (purple). (B) Crystal structure of ALK in complex with <b>5a</b> (yellow stick). Hydrogen bond and charge–charge interaction are shown with red and green dashed lines, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The urea moiety and the <i>tert</i>-butylisoxazole group of <b>5a</b> are located at the additional hydrophobic pocket, created by the shift of the DFG motif from the DFG-in to the DFG-out conformation. The urea moiety forms one hydrogen bond with the backbone of Asp1270 in the DFG motif and forms two hydrogen bonds with the side chain of Glu1167 in αC-helix. The <i>tert</i>-butylisoxazole group extends into the allosteric site surrounded by the HRD motif and the αC-helix, where it makes extensive hydrophobic interactions with Ile1171, Phe1174, Ile1179, Phe1245, His1247, and Ile1268. That these interactions between the <i>tert</i>-butyl moiety and these hydrophobic residues contribute to the activity of <b>5a</b> is evidenced by compounds <b>5d</b>, <b>5e</b>, and <b>5f</b>. When the <i>tert</i>-butyl moiety is replaced with the smaller alkyl substituents, such as isopropyl (<b>5d</b>), ethyl (<b>5e</b>), or methyl (<b>5f</b>), the activity decreases accordingly, suggesting that the hydrophobicity of the alkyl substituents correlates with the activity of compounds. Indeed, superimposition of the crystal structure of ALK/<b>5a</b> and of ALK/<b>5d</b> shows that the isopropyl group of <b>5d</b> resulted in loss of the hydrophobic interactions (Phe1174, Ile1179, and Phe1245) compared with the <i>tert</i>-butyl group of <b>5a</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Superposition of the crystal structure of ALK/<b>5a</b> with ALK/<b>5d</b> gave a rmsd of 0.354 Å for 284 C<sub>α</sub> atom. Both the <i>tert</i>-butyl group of <b>5a</b> (yellow) and the isopropyl group of <b>5d</b> (cyan) extended into the hydrophobic pocket. As compared with the structure of ALK/<b>5a</b>, the isopropyl group of <b>5d</b> loses the interactions with Phe1174, Ile1179, and Phe1245 (marked in green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> <b>5a</b> Induces a Dramatic Conformational Change of ALK</h3><div class="NLM_p last">Superimposition of the ALK/<b>5a</b> complex structure with the apo ALK structure reveals that ALK undergoes significant conformational changes upon <b>5a</b> binding. The root-mean-square deviation (rmsd) of these two aligned structures is 2.11 Å for 282 C<sub>α</sub> atoms. Binding of <b>5a</b>, a type II kinase inhibitor, not only induces the conformational flipping of DFG motif but also results in the reconstitution of the αC-helix, activation loop (A-loop), and juxtamembrane (JM) domain.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> (i) Rearrangement of Activation Loop (A-Loop) and αC-Helix</h3><div class="NLM_p">To elucidate the conformational change induced by <b>5a</b>, the apo ALK crystal structure was solved to a resolution of 1.50 Å and compared with ALK/<b>5a</b> complex structure (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). There are various differences between these two structures. First, in the apo ALK structure, the nonconserved region of the A-loop following the DFG motif adopted a short helix (α-AL, residue 1272–1280) and positioned orthogonally underneath the αC-helix to form the salt bridge and hydrogen bond interactions with αC-helix (i.e., Gln1159 in αC-helix/Arg1279 in α-AL; Asp1163 in αC-helix/Arg1275 and Arg1279 in α-AL; Glu1167 in αC-helix/Arg1275 in α-AL). Tyr1278, located in the terminal of α-AL, is an autophosphorylation site in the A-loop and plays an important role in the regulation of ALK activation.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Through edge-to-face, π–π interactions with Tyr1096 and the hydrogen bonding with backbone nitrogen atom of Ser1097 in JM domain, Tyr1278 serves as the latch which clamps the orientation of αC-helix and stabilizes the JM domain in an antiparallel β-turn conformation (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). In comparison, binding of <b>5a</b> unfolded the α-AL to a nonstructural loop and moved α-AL away from the αC-helix (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B), resulting in the loss of the salt bridge and hydrogen bond interactions with αC-helix. The loss of the interactions between α-AL and αC-helix moves the αC-helix 2 Å away from C-lobe to an open state (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). Consequently, the interactions of Tyr1278 in α-AL with Tyr1096 and S1097 in the JM domain were concurrently lost.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Spatial arrangement of the αC-helix (cyan), α-AL helix (purple), and JM domain (green) in apo ALK structure. (B) Spatial arrangement of the αC-helix, α-AL, and JM domain in ALK/<b>5a</b> structure. (C) Comparison of the structures of apo ALK (pale purple) and ALK/<b>5a</b> (pale pink). Binding of <b>5a</b> unfolds the α-AL to a nonstructural loop and moves α-AL away from the αC-helix, which consequently shifts the αC-helix away from C-lobe to an open state. In addition, the JM domain concurrently transforms from the antiparallel β-turn conformation to the helix conformation. Red arrow indicates that αC-helix shifts outward to an open state upon the binding of <b>5a</b>. (D) A 60° rotated view of (C). Binding of <b>5a</b> induces the dramatic conformation change of JM domain. Reorientation of αC-helix to an open state upon the binding of <b>5a</b> would clash with JM domain (explosion drawing represents the vdw overlapping and steric clashing).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Second, <b>5a</b> flipped the DFG motif from an in to an out conformation. This conformational change altered the internal architecture of the ALK kinase domain. In the apo ALK structure, the neighboring residues (His1247 in HRD motif, Phe1271 in DFG motif, Ile1171 in the αC-helix, and Cys1182 in the β4-strand) constitute the functional hydrophobic network, which is designated as regulatory spine (R-spine) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). The backbone nitrogen of His1247 in R-spine hydrogen-bonded to the side chain of Asp1311 in the helix-F served as the base for the R-spine. Studies have shown that assembling and disassembling of the R-spine regulates the activity of protein kinase.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29-31)</a> Upon the binding of <b>5a</b> to ALK, the R-spine is disrupted by the movement of Phe1271 in the DFG-motif and reaccommodation by the <i>tert</i>-butylisoxazole group of <b>5a</b>. In addition, the catalytic spine (C-spine) also showed differences between the apo ALK and ALK/<b>5a</b> complex structures. It also regulates activity of protein kinase; however, assembling or disassembling of the C-spine is dependent on the incorporation of ATP or substrate. In the apo ALK structure, without the ATP or substrate, the C-spine is incomplete, while in the ALK/<b>5a</b> complex structure, the pyrazole group of <b>5a</b> interconnects the N-lobe and C-lobe through neighboring hydrophobic residues and completes the C-spine (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Catalytic spine (C-spine, pale blue) and regulatory spine (R-spine, pale green) coordinated the internal architecture of ALK. Both hydrophobic spines reached from the N-lobe to the C-lobe of the kinases and anchored to the F-helix. (B) Incorporation of <b>5a</b> completed the C-spine and R-spine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> (ii) Conformational Change of Juxtamembrane (JM) Domain</h3><div class="NLM_p">Most of the published ALK structures revealed that the juxtamembrane (JM) domain (residues 1087–1115), flanked by the αC-helix, contain an N-terminal helix segment (residues 1086–1092) and an antiparallel β-turn motif (residues 1096–1103) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). The β-turn motif in the JM domain is a unique feature for ALK, compared with other kinase structures. The hydrophobic residues from the JM domain, including Ile1088, Met1089, Pro1094, Tyr1096, Phe1098, Ile1105, and Leu1108, facilitate the close packing of the JM domain on the interface of αC-helix. In addition, the interactions between the JM domain (Tyr1096 and Ser1097) and the α-AL (Tyr1278) also assist the stabilization of the ALK kinase domain in the native conformation (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A).</div><div class="NLM_p">Interestingly, upon the binding of <b>5a</b>, the JM domain transformed from the antiparallel β-turn conformation to the helix conformation (residue 1096–1102), with concomitant disorder of the N-terminal helix segment of the JM domain (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). This conformational change in the JM domain results in significant loss of the contacted interface area with αC-helix and disrupts the interactions with α-AL. Superimposition of the apo ALK structure with the ALK/<b>5a</b> complex structure revealed that the opened state αC-helix induced by the binding of <b>5a</b> would clash with the JM domain (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). Ile1088 and Met1089 in the N-terminal JM domain experience a steric clash with the Glu1158 and Glu1161 in the N-terminal αC-helix, while Tyr1096 and Phe1098 in the β-turn motif of the JM domain clash with Ile1170 and Phe1174 in the C-terminal part of αC-helix, respectively (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). To avoid this, the JM domain undergoes a conformational change from β-turn motif to the helix conformation and also disorders the N-terminal helix segment to a more flexible conformation to accommodate the opened state αC-helix.</div><div class="NLM_p">As a result of the conformational change of the JM domain in the ALK<b>/5a</b> structure, two potential autophosphorylation tyrosine residues, Tyr1092 and Tyr1096,<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> were repositioned. In the apo-ALK structure, Tyr1092 in the N-terminal helix segment was exposed to solvent region while Tyr1096 was deeply immersed in a hydrophobic pocket composed of Phe1098, Leu1169, Ile1170, Lys1173, Phe1174, Phe1245, and Tyr1278 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). However, in the ALK/<b>5a</b> structure, Tyr1092 was structurally disordered and Tyr1096 was exposed to solvent, where it forms hydrogen bonds with Asp1163 in the αC-helix and Asn1093 in the JM domain (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). In the previous studies, Tyr1096 has been identified as the phosphoprotein binding domain (PBD) for insulin receptor substrate1 (IRS1) and Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> IRS1 binds to pTyr1096 and activates the downstream of cell division of the Ras/Erk1/2 signal pathway. It is suggested that binding of <b>5a</b> to ALK results in reconstitution of the JM domain and alters the interaction network of Tyr1096 with its surroundings, which may affect the autoinhibition state of ALK and the downstream signaling pathway inhibition. Tyr1096 not only is a key autophosphorylation site but might also serve as a structural switcher to regulate the JM domain autoinhibition and kinase catalytic activity.</div><div class="NLM_p">The conformational change of the JM domain induced by the type II kinase inhibitors kinase has also been observed for other tyrosine kinases, including FLT3/1-(5-<i>tert</i>-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl]urea (AC220) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF">4XUF</a>),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> c-KIT/imatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and VEGFR/sorafenib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD">4ASD</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In addition, reposition of those autophosphorylation tyrosine residues has always accompanied rearrangement of the JM domain. For example, in the c-KIT structure, Tyr568 and Tyr570 are key autophosphorylation tyrosine residues that regulate the autoinhibition state of c-KIT. The binding of imatinib to c-KIT led to the rearrangement of the JM domain and the repositioning of Tyr568 and Tyr570. However, most of those type II inhibitors would directly clash with the JM domain; hence, the conformational change of JM domain is required to avoid this. In contrast, <b>5a</b> is far away and has no directly steric clash with the JM domain as revealed in the ALK/<b>5a</b> complex structure. <b>5a</b> induced an allosteric effect through the conformational change of αC-helix moving toward the JM domain and consequently led to the rearrangement of JM domain to be compatible with the opened state of αC-helix.</div><div class="NLM_p last">In conclusion, <b>5a</b> induced conformation changes in the α-AL, αC-helix, and JM domain and thus disrupted the extensive interaction networks in the ALK structure. Consequently, the interactions between Tyr1278 in α-AL and Tyr1096 and S1097 in the JM domain were lost. These results suggest that <b>5a</b> altered the interaction network formed by αC-helix, α-AL, and JM domain, which regulates the autoinhibition and activation of ALK.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Impact of Substituted-Urea Tail Moiety on <b>5a</b> Binding</h3><div class="NLM_p">As revealed in the SAR study, <b>4</b> did not impart any ALK inhibitory activity (IC<sub>50</sub> > 10 μM), suggesting that the urea-substituted tail moiety was the dominant feature of <b>5a</b> and contributed to the kinase inhibition activities. In order to evaluate the effect of the urea-substituted tail group on the binding of ALK at the molecular level, <b>4</b>, a non-urea aryl analogue of <b>5a</b>, was soaked into ALK crystal and the structure of the complex resolved to a resolution of 1.87 Å. The electron density map clearly shows that <b>4</b>, presented as a type I inhibitor, bound in the DFG-in conformation.</div><div class="NLM_p">The structure of ALK/<b>4</b> is significantly different from the ALK/<b>5a</b> structure. Superimposition of these two structures gave a rmsd of 2.147 Å for 280 C<sub>α</sub> atoms. First, in the ALK/<b>5a</b> structure, the DFG motif adopts the out conformation to allocate the urea-substituted tail and makes the face-to-edge π–π interactions with the pyrazolylamine scaffold of <b>5a</b>, while in the ALK/<b>4</b> structure, in the absence of the urea-substituted tail, the DFG motif adopts the in conformation and has no direct interactions with the pyrazolylamine scaffold of <b>4</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Superposition of the crystal structure of ALK/<b>5a</b> with ALK/<b>4</b>. Binding of <b>5a</b> induces the conformational changes of αC-helix, A-loop, and JM domain. In the absence of the substituted-urea tail moiety, no ligand-induced conformational changes were observed in ALK/<b>4</b> structure. (B) Interaction network of <b>4</b> with ALK. (C) The P-loop of ALK/<b>4</b> adopts a distinct conformation among the different ALK structures. Bending of the P-loop oriented Phe1127 into the ATP binding site and directly stacked to the tolyl group of <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Second, in the ALK/<b>5a</b> structure, the αC-helix exhibits the open state conformation and the Glu1167 in the αC-helix forms hydrogen bonding interactions with the urea moiety (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). The JM domain was fully unfolded due to the allosteric effect derived from movement of αC-helix. However, in the ALK/<b>4</b> structure, the αC-helix adopts the close state conformation and the Glu1167 interacts with the amino substituent on the 4-position of the tolyl group through a water-mediated hydrogen bond (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). Without the ligand-induced allosteric effect, the αC-helix and JM domain of ALK/<b>4</b> structure would adopt a similar conformation to the apo ALK structure (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A) and other published ALK complex structures with type I inhibitors.</div><div class="NLM_p">As revealed in the structural biology studies of <b>5a</b> and <b>4</b>, <b>5a</b> is a type II inhibitor bound to the DFG-out conformation, while <b>4</b> is a type I inhibitor bound to the DFG-in conformation. Many reports have shown that the binding kinetics of type II inhibitors and type I inhibitors are different.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Therefore, the binding kinetics of <b>5a</b> and <b>4</b> were further evaluated by surface plasmon resonance (SPR). Binding of <b>4</b> showed a fragment-like squared-shaped sensorgram, indicating very fast on and fast off rates (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_001.pdf" class="ext-link">Supporting Information, Figure S1</a>). In contrast, the association rate (<i>k</i><sub>on</sub>) and dissociation rate (<i>k</i><sub>off</sub>) for <b>5a</b> were 5.17 × 10<sup>4</sup> 1/Ms and 2.4 × 10<sup>–3</sup> 1/s, respectively, suggesting that <b>5a</b> bound to ALK with slow association and dissociation rates. It has been reported that these slow binding kinetics correlate with protein conformation change induced by the ligand binding.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> The urea-substituted tail moiety endows <b>5a</b> with a characteristic slow off-rate, consistent with the requirement of DFG motif conformational change.</div><div class="NLM_p last">In addition to the ALK/<b>5a</b> structure, the structure of ALK/<b>4</b> was also compared with the apo ALK structure. The most significant difference between ALK/<b>4</b> and apo ALK structures is the conformation change of the phosphate-binding loop (P-loop) upon the binding of <b>4</b>. In the ALK/<b>4</b> structure, the P-loop adopts a bent conformation and orients the conserved aromatic residue Phe1127 into the catalytic site, directly stacked onto the tolyl group of <b>4</b> by edge-to-face π–π interaction, whereas the P-loop adopted an extended conformation in most of the ALK structures (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). In many kinase/inhibitor complex structures, bending of the P-loop always creates the face-to-face or edge-to-face aromatic interaction between the conserved aromatic residue and inhibitors such as Aurora-A/<i>N</i>-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1<i>H</i>-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide (VX-680) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E5A">3E5A</a>),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> c-Abl/imatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and p38α/1-[5-<i>tert</i>-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea (BIRB796) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> complex structures.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Comparing <b>5a</b> with Others ALK Kinase Inhibitors</h3><div class="NLM_p">To elucidate the similarities and differences of structure conformation and protein–ligand interactions, crystal structures of <b>5a</b> and different ALK kinase inhibitor (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A) complex structures were superimposed.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Schematic representation of type I inhibitor crizotinib and type II inhibitors, <b>6</b> and <b>5a</b>. (B, C) Superimposition of the ALK/<b>5a</b> structure with ALK/crizotinib structure. (D, E) Superimposition of the ALK/<b>5a</b> structure with ALK/<b>6</b>. Hydrogen bonds between ALK/<b>5a</b> and ALK/crizotinib (or ALK/<b>6</b>) are shown with red and green dashed lines, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Superimposition of <b>5a</b> and crizotinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>)<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> revealed that the structural conformations are quite different (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> B and <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> C). The structure of ALK/crizotinib resembles apo ALK, and the binding of crizotinib to ALK does not induce dramatic conformational changes. The conformation of ALK/crizotinib is the DFG-in conformation and the αC-helix adopts the close state accompanying the JM domain in the antiparallel β-sheets conformation. In contrast, ALK/<b>5a</b> was found to present the DFG-out conformation, where the αC-helix adopts the open state accompanying the JM domain in the helix conformation.</div><div class="NLM_p">Both the pyrazolyl-5-amine of <b>5a</b> and pyridine-2-amine of crizotinib (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A, highlighted in cyan) formed hydrogen bonds to the hinge residues Glu1197 and Met1199. However, the most significant differences between <b>5a</b> and crizotinib are that the <i>tert</i>-butylisoxazole urea moiety (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A, highlighted in purple) of <b>5a</b> extended to the allosteric pocket, whereas the 2,6-dichloro-3-fluorophenyl group (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A, highlighted in red) of crizotinib was oriented to small hydrophobic cavity underneath the P-loop instead. Conformational changes in ALK induced by <b>5a</b>, accompanied by additional interactions with the allosteric pocket, led to the slow-binding kinetics of <b>5a</b> as compared with crizotinib. The binding association and dissociation rate constants of <b>5a</b> (<i>k</i><sub>on</sub> = 5.17 × 10<sup>4</sup> 1/Ms; <i>k</i><sub>off</sub> = 2.4 x10<sup>–3</sup> 1/s) were about 226-fold and 15-fold slower than crizotinib (<i>k</i><sub>on</sub> = 1.17 × 10<sup>7</sup> 1/Ms; <i>k</i><sub>off</sub> = 3.55 × 10<sup>–2</sup> 1/s). The slower association rate of <b>5a</b> may due to the higher energy barrier for inducing ALK conformational change. Slow dissociation rate has been shown to be correlated with the potency and prolonged drug effects both in vitro and in vivo.<a onclick="showRef(event, 'ref18 ref37 ref38 ref41'); return false;" href="javascript:void(0);" class="ref ref18 ref37 ref38 ref41">(18, 37, 38, 41)</a></div><div class="NLM_p">Next, the structure of <b>5a</b> was further compared with <b>6</b>, a type II ALK inhibitor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FNY">4FNY</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Superimposing the crystal structures of <b>5a</b> with <b>6</b> show differences between these two structures. First, the JM domain is visible in ALK/<b>5a</b> structure but absent in ALK/<b>6</b> structure (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>D). Binding of <b>5a</b> reorients the αC-helix to an open state and allosteric effects regulate the refolding of the JM domain to a short helix segment. However, in the ALK/<b>6</b> structure, the refolding of the JM domain is not observed due to the disordered in this region. Second, in the ALK/<b>5a</b> structure, α-AL was unfolded to a nonstructural loop and moved away from the αC-helix while α-AL was completely invisible in the ALK/<b>6</b> structure.</div><div class="NLM_p last">Moreover, by superimposing the structure complex of <b>6</b> onto <b>5a</b>, it revealed that pyrazolyl-5-amine (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A, highlighted in cyan) of <b>5a</b> formed three hydrogen bonds with hinge residues Glu1197 and Met1199, while the nitrogen atom of the dimethoxyquinoline group (highlighted in cyan) in <b>6</b> made one hydrogen bond with Met1199. Moreover, the phenyl group together with the <i>N</i>-methylpiperidine group of <b>5a</b> extend to the solvent exposed region of ALK to form hydrophobic interactions with the surrounding residues and made charge–charge interactions with the acidic zone. In contrast, in ALK/<b>6</b> complex structure, the solvent exposed region is unoccupied and two methoxy substitutions at quinoline group of <b>6</b> were much less exposed to the bulk solvent and had no interactions with the acidic zone.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this study, <b>5a</b>, a 3-phenyl-1<i>H</i>-5-pyrazolylamine-based compound bearing a urea substituent, was identified by in-house kinase screening as a novel ALK inhibitor. Further structural biology studies of <b>5a</b> with ALK revealed that <b>5a</b> adopts a type II binding mode. The urea-substituted moiety of <b>5a</b> flips the DFG-motif from an in to an out conformation and coordinates the orientation of <b>5a</b> through the hydrogen bonds with Glu1167 in the αC-helix and Asp1270 in DFG motif. In addition, the <i>tert</i>-butyl group of <b>5a</b> allows for a hydrophobic interaction with the allosteric pocket created by the conformational change of DFG motif. Interestingly, binding of <b>5a</b> induces a dramatic conformational change of ALK by spatial rearrangement of A-loop, αC-helix, and JM domain. <b>5a</b> unfolded the A-loop to a nonstructural loop and moved the α-AL away from the αC-helix, resulting in the loss of the salt bridge and hydrogen bond interactions with αC-helix. The loss of the interactions between α-AL and the αC-helix reorients the αC-helix 2 Å away from the C-lobe to an opened state. Furthermore, the binding of <b>5a</b> results in the transformation of the JM domain from the antiparallel β-turn conformation to the helix conformation and the disorder of N-terminal helix segment of JM domain. The conformational change of JM domain significantly reduces the contacted interface area with αC-helix and disrupts the interactions with α-AL. As a consequence of this conformational change and spatial rearrangement, the binding of <b>5a</b> to the ALK kinase domain alters the interaction network of Tyr1096, an important autophosphorylation residue located in juxtamembrane domain, and may affect the autoinhibition mechanism of ALK and downstream signal pathway regulation.</div><div class="NLM_p">Further comparison of the cocrystal structures of ALK/<b>5a</b> with ALK/<b>4</b> revealed that the substituted-urea tail moiety controls the conversion between the DFG-in and DFG-out conformation and reallocates the A-loop, αC-helix, and JM domain. Further studies of <b>5a</b> and <b>4</b> showed these two compounds have different molecular properties, such as the polarizability, lipophilicity, and molecular surface area. The polarizabilities of compounds <b>5a</b> and <b>4</b> are 62.85 Å<sup>3</sup> and 46.99 Å<sup>3</sup>, respectively, indicating they have different electronic properties. The log <i>P</i> values of compound <b>5a</b> and <b>4</b> are 4.54 and 2.61, respectively, suggesting <b>5a</b> exhibited higher lipophilicity. Moreover, the molecular surface area of compound <b>5a</b> is 863.6 Å<sup>2</sup> and that of compound <b>4</b> is 615.3 Å<sup>2</sup>, suggesting they have different impacts on steric effects with the protein. The differences in physicochemical and structural properties of inhibitors would also contribute to the conversion between the type I and type II binding modes and the conformational change of ALK.</div><div class="NLM_p">Furthermore, the ligand efficiency (LE) of <b>5a</b> and analogues was calculated (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). On the basis of the structural observation from ALK/<b>5a</b>, it is suggested that replacing the <i>N</i>-methylpiperazine group of <b>5a</b> with a guanidine group may potentially provide electrostatic interactions and hydrogen bond interactions with the acid region in ALK to improve the potency (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_001.pdf" class="ext-link">Figure S3 in the Supporting Information</a>). In addition, the replacement of <i>N</i>-methylpiperazine group of <b>5a</b> with a guanidine group would reduce the molecular weight (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_001.pdf" class="ext-link">Figure S3 in the Supporting Information</a>), which would potentially improve the ligand efficiency of <b>5a</b>.</div><div class="NLM_p last">To the best of our knowledge, this is the first structural biology study to directly observe how changes in a small molecule can regulate the switch between the type I and type II binding modes and induce dramatic conformational changes in protein structures. Our results are expected to be useful for activation/inhibition mechanism studies of ALK and should give insights into the development of the novel type II inhibitors for ALK or the other kinases in the future.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> ALK Expression, Purification, and Crystallization</h3><div class="NLM_p">Human ALK kinase domain (residues 1084–1410) was expressed using baculovirus system (Sf21 cells). The residue Cys1097 was mutated to serine to facilitate protein expression and crystallization as reported previously.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Cell suspension was centrifuged at 4500 rpm for 15 min, and the cell pellet was suspended in Tris buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM imidazole, and 1 mM TCEP) and lysed by sonication. The supernatant was filtered with 0.22 filters and loaded onto HiTrap HP Ni-affinity column (GE Life Sciences). ALK was eluted with 75 mM imidazole in wash buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) and buffer exchanged to factor Xa cleavage buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM CaCl<sub>2</sub>, pH 8.0) by Hiprep 26/10 desalting column (GE Life Sciences). His tag was then removed by factor Xa (Novagen) cleavage at 4 °C. ALK was finally exchanged to the protein buffer (25 mM Tris-HCl, 125 mM NaCl, 14 mM β-ME, pH 8.5) and concentrated to 12–15 mg/mL.</div><div class="NLM_p last">ALK was crystallized by sitting drop method. Equal volumes of reservoir solution (18% PEG2000 MME, 0.1 M Tris-HCl, pH 8.6) and ALK were mixed and grown at 4 °C. ALK crystals were soaked with 0.5 mM tested compounds for more than 6 h. The ALK crystal was then quickly immersed in the reservoir solution with additional 20% ethylene glycol and then cooled in liquid nitrogen. Diffraction data were collected at beamline BL15A1 (NSRRC, Taiwan) and beamlines BL12B2 and 44XU (Spring-8, Japan). Data were processed by HKL2000 program.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The phase of initial ALK structure was resolved by molecular replacement using PHENIX.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Structure refinement and model building were performed using PHENIX and COOT-0.8.1.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Figures were prepared with PyMOL, version 1.7.2 (Schrodinger, LLC).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Kinase Inhibition Assay</h3><div class="NLM_p last">In vitro kinase assays were carried out in 96-well plate with tested compounds in the reaction buffer (25 mM HEPES, pH 7.4, 10 mM MgCl<sub>2</sub>, 4 mM MnCl<sub>2</sub>, 0.5 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM DTT, 0.02% TritonX-100, and 0.01% BSA). A total of 50 μL of reaction mixture contained the testing compounds, l μM ATP (Sigma), 2 μM polyGlu<sub>4</sub>:Tyr peptide (Sigma), and 100 ng of ALK protein. The reaction was performed at 30 °C for an hour. The kinase assay was run with phosphorylated ALK. Equal volume of kinase-Glo plus reagent (Promega) was added after 1 h of incubation. The reaction mixture was transferred to a black plate, and the luminescence was recorded by Wallac Vector 1420 multilabel counter (PerkinElmer, Shelton, CT, USA).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Surface Plasmon Resonance (SPR)</h3><div class="NLM_p last">ALK was immobilized on the CM5 chip (GE Life Sciences) using amine-coupling method. The immobilization procedure was based on the default setting on the Biacore-T200 control software. PBS buffer (pH 7.5, contained 5% fresh DMSO) was used as the running buffer. <b>5a</b> (50 mM) in 100% DMSO was dissolved in 1× running buffer to give the analyte solution concentration 1.25–0.046 μM. Crizotinib (1 mM) was used to prepare analyte solution, 40–2.5 nM. Three cycles of start-up and one cycle of solvent correction were performed before sample-cycle run. Solvent correction (8 concentrations, ranging from 4.5% to 5.8% DMSO in 1× PBS, pH 8.5) was used to adjust response error due to the content mismatch between running buffer and sample. The LMW single-cycle kinetics analysis consisted of 120 s of association (30 μL/min), 300 s of dissociation (30 μL/min), 30 s of carry-over control (40 μL/min), and finally 60 s of surface stabilization (30 μL/min). Except five concentrations of sample injection, two double reference cycle-runs were repeated. Biacore-T200 evaluation software, version 2.0, was used for the affinity and kinetic analysis.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Molecular Properties Calculation</h3><div class="NLM_p last">The polarizability and molecular surface area of compound <b>5a</b> and <b>4</b> were calculated by MarvinSketch program implemented in ChemAxon.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The log <i>P</i> value of compounds <b>5a</b> and <b>4</b> were calculated by Chemdraw Ultra 7.0.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry Methods</h3><div class="NLM_p last">All commercial chemicals and solvents are reagent grade and were used without further treatment unless otherwise noted. <sup>1</sup>H NMR spectra were obtained with a Varian Mercury-300 or a Varian Mercury-400 spectrometer. Chemical shifts were recorded in parts per million (ppm, δ) and were reported relative to the solvent peak or TMS. LC/MS data were measured on an Agilent MSD-1100 ESI-MS/MS system. High-resolution mass spectra (HRMS) were measured with a Thermo Finnigan (TSQ Quantum) electrospray ionization (ESI) mass spectrometer. Flash column chromatography was done using silica gel (Merck Kieselgel 60, no. 9385, 230–400 mesh ASTM). Reactions were monitored by TLC using Merck 60 F<sub>254</sub> silica gel glass backed plates (5 cm × 10 cm); zones were detected visually under ultraviolet irradiation (254 nm) or by spraying with phosphomolybdic acid reagent (Aldrich) followed by heating at 80 °C. All starting materials and amines were commercially available unless otherwise indicated. The purity of compounds was determined by a Hitachi 2000 series HPLC system. Compound purities were determined by reverse phase C<sub>18</sub> column (Agilent ZORBAX Eclipse XDB-C18 5 μm, 4.6 mm × 150 mm) under the following gradient elution condition: mobile phase A of acetonitrile (10–90%, 0–45 min) and mobile phase B of 10 mM NH<sub>4</sub>OAc aqueous solution containing 0.1% formic acid (90–10%, 0–45 min). The flow rate was 0.5 mL/min, and the injection volume was 20 μL. The system operated at 25 °C. Peaks were detected at 254 nm.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>-[3-(4-Amino-3-methylphenyl)-1<i>H</i>-pyrazol-5-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide (<b>4</b>)</h3><div class="NLM_p last">Mp 229–230 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 11.12 (s, 1H), 8.11 (d, <i>J</i> = 8.1 Hz, 2H), 8.00 (d, <i>J</i> = 8.4 Hz, 1H), 7.84 (d, <i>J</i> = 8.1 Hz, 2H), 7.77 (s, 1H), 7.70 (d, <i>J</i> = 8.1 Hz, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 1H), 7.03 (s, 1H), 4.51 (bs, 2H), 3.78–3.30 (m, 6H), 3.15 (s, 3H), 2.90–2.70 (m, 4H), 2.43 (s, 3H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>6</sub>O: 404.23; found, 405.2 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 14.09 min, 95.0%.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>1-(3-4-[([5-(<i>tert</i>-Butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1<i>H</i>-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (<b>5a</b>)</h3><div class="NLM_p last">Mp 263–264 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 10.78 (s, 1H), 9.95 (s, 1H), 8.35 (s, 1H), 7.99–7.97 (m, 3H), 7.73 (s, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 2H), 7.11 (s, 1H), 6.48 (s, 1H), 3.52 (s, 2H), 3.35 (s, 4H), 2.37 (s, 4H), 2.30 (s, 3H), 2.15 (s, 3H), 1.30 (s, 9H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>38</sub>N<sub>8</sub>O<sub>3</sub>: 570.31; found, 571.4 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>31</sub>H<sub>39</sub>N<sub>8</sub>O<sub>3</sub>, 571.3145; found, 571.3136 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 22.66 min, 99.1%.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-[3-(4-{[(3-Fluorophenyl)carbamoyl]amino}phenyl)-1<i>H</i>-pyrazol-5-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide (<b>5b</b>)</h3><div class="NLM_p last">Mp 225–227 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.80 (s, 1H), 10.78 (s, 1H), 9.07 (s, 1H), 8.99 (s, 1H), 7.99 (d, <i>J</i> = 8.0 Hz, 2H), 7.69 (d, <i>J</i> = 8.4 Hz, 2H), 7.54 (d, <i>J</i> = 8.8 Hz, 2H), 7.49 (s, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 2H), 7.31 (q, <i>J</i> = 7.8 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 6.97 (s, 1H), 6.79 (td, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.67 (s, 2H), 2.62–2.00 (m, 8H), 2.16 (s, 3H). MS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>30</sub>FN<sub>7</sub>O<sub>2</sub>: 527.24; found, 528.2 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 21.21 min, 98.7%.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>1-[3-(4-[([5-(<i>tert</i>-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1<i>H</i>-5-pyrazolyl]-4-[(4-methylpiperazino)methyl]benzamide (<b>5c</b>)</h3><div class="NLM_p last">Mp 226–227 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 10.82 (s, 1H), 10.71 (s, 1H), 9.50 (s, 1H), 7.98 (d, <i>J</i> = 8.1 Hz, 2H), 7.72 (d, <i>J</i> = 8.1 Hz, 2H), 7.41 (d, <i>J</i> = 8.1 Hz, 2H), 7.36 (t, <i>J</i> = 8.4 Hz, 2H), 7.02 (t, <i>J</i> = 5.7 Hz, 2H), 6.38 (s, 1H), 4.35 (d, <i>J</i> = 5.7 Hz, 2H), 3.52 (s, 2H), 3.25 (s, 4H), 2.37 (s, 4H), 2.15 (s, 3H), 1.27 (s, 9H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>38</sub>N<sub>8</sub>O<sub>3</sub>: 570.31; found, 571.4 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>31</sub>H<sub>39</sub>N<sub>8</sub>O<sub>3</sub>: 571.3140; found, 571.3147 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 20.98 min, 98.1%.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4-[(4-Methylpiperazin-1-yl)methyl]-<i>N</i>-{3-[3-methyl-4-({[5-(propan-2-yl)-1,2-oxazol-3-yl]carbamoyl}amino)phenyl]-1<i>H</i>-pyrazol-5-yl}benzamide (<b>5d</b>)</h3><div class="NLM_p last">Mp 235–236 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.80 (s, 1H), 10.78 (s, 1H), 9.93 (s, 1H), 8.35 (s, 1H), 8.05–7.95 (m, 3H), 7.62 (s, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 2H), 7.00 (s, 1H), 6.49 (s, 1H), 3.52 (s, 2H), 3.02 (sep, <i>J</i> = 7.2 Hz, 1H), 2.60–2.00 (m, 8H), 2.37 (s, 3H), 1.25 (d, <i>J</i> = 7.2 Hz, 6H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub>: 556.29; found, 557.3 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>30</sub>H<sub>37</sub>N<sub>8</sub>O<sub>3</sub>: 557.2989; found, 557.2994 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 21.79 min, 99.9%.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>1-3-[4-([(5-Ethyl-3-isoxazolyl)amino]carbonylamino)-3-methylphenyl]-1<i>H</i>-5-pyrazolyl-4-[(4-methylpiperazino)methyl]benzamide (<b>5e</b>)</h3><div class="NLM_p last">Mp 225–227 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.80 (s, 1H), 10.77 (s, 1H), 9.91 (s, 1H), 8.36 (s, 1H), 7.99–7.97 (m, 3H), 7.62–7.56 (m, 2H), 7.41 (d, <i>J</i> = 8.0 Hz, 2H), 7.00 (s, 1H), 6.52 (s, 1H), 3.50 (s, 2H), 3.17 (d, <i>J</i> = 4.8 Hz, 3H), 2.67 (q, <i>J</i> = 7.6 Hz, 2H), 2.37 (br s, 8H), 2.15 (s, 3H), 1.22 (t, <i>J</i> = 7.6 Hz, 3H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub>: 542.28; found, 543.3 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>29</sub>H<sub>35</sub>N<sub>8</sub>O<sub>3</sub>: 543.2832; found, 543.2839 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 20.16 min, 95.1%.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>1-3-[3-Methyl-4-([(5-methyl-3-isoxazolyl)amino]carbonylamino)phenyl]-1<i>H</i>-5-pyrazolyl-4-[(4-methylpiperazino)methyl]benzamide (<b>5f</b>)</h3><div class="NLM_p last">Mp 155–157 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 10.78 (s, 1H), 9.89 (s, 1H), 8.36 (s, 1H), 7.99–7.97 (m, 3H), 7.62 (s, 1H), 7.57 (d, <i>J</i> = 8.7 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 2H), 7.00 (s, 1H), 6.52 (s, 1H), 3.52 (s, 2H), 3.36 (s, 4H), 2.37 (s, 7H), 2.30 (s, 3H), 2.15 (s, 3H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>32</sub>N<sub>8</sub>O<sub>3</sub>: 528.26; found, 529.3 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>28</sub>H<sub>32</sub>N<sub>8</sub>O<sub>3</sub>: 528.2597; found, 528.2598 (M<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 18.55 min, 99.5%.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>1-(3-4-[([5-(<i>tert</i>-Butyl)-3-isoxazolyl]aminocarbonyl)amino]phenyl-1<i>H</i>-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (<b>5g</b>)</h3><div class="NLM_p last">Mp 247–248 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 10.79 (s, 1H), 9.73 (s, 1H), 9.23 (s, 1H), 7.98 (d, <i>J</i> = 8.1 Hz, 2H), 7.69 (d, <i>J</i> = 8.4 Hz, 2H), 7.54 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 8.1 Hz, 2H), 6.97 (s, 1H), 6.52 (s, 1H), 3.51 (d, <i>J</i> = 5.1 Hz, 2H), 3.28 (t, <i>J</i> = 4.8 Hz, 4H), 2.37 (t, <i>J</i> = 4.8 Hz, 4H), 2.16 (s, 3H), 1.30 (s, 9H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub>: 556.29; found, 557.4 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>30</sub>H<sub>37</sub>N<sub>8</sub>O<sub>3</sub>: 557.2993; found, 557.2988 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 22.29 min, 93.3%.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-[(4-Methylpiperazin-1-yl)methyl]-<i>N</i>-{3-[4-({[5-(propan-2-yl)-1,2-oxazol-3-yl]carbamoyl}amino)phenyl]-1<i>H</i>-pyrazol-5-yl}benzamide (<b>5h</b>)</h3><div class="NLM_p last">Mp 229–230 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.82 (s, 1H), 10.78 (s, 1H), 9.60 (s, 1H), 9.09 (s, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 2H), 7.69 (d, <i>J</i> = 8.8 Hz, 2H), 7.54 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 7.6 Hz, 2H), 6.98 (s, 1H), 6.54 (s, 1H), 3.52 (s, 2H), 3.03 (sep, <i>J</i> = 6.8 Hz, 1H), 2.60–2.02 (m, 8H), 2.16 (s, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 6H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub>: 542.28; found, 543.3 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 21.28 min, 97.2%.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>1-(3-4-[([5-(<i>tert</i>-Butyl)-3-isoxazolyl]aminocarbonyl)amino]phenyl-1<i>H</i>-5-pyrazolyl)-4-(2-tetrahydro-1<i>H</i>-1-pyrrolylethoxy)benzamide (<b>5i</b>)</h3><div class="NLM_p last">Mp 256–257 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.79 (s, 1H), 10.68 (s, 1H), 9.59 (s, 1H), 8.99 (s, 1H), 8.02 (d, <i>J</i> = 8.8 Hz, 2H), 7.69 (d, <i>J</i> = 8.8 Hz, 2H), 7.54 (d, <i>J</i> = 8.4 Hz, 2H), 7.04 (d, <i>J</i> = 8.8 Hz, 2H), 6.96 (bs, 1H), 6.52 (s, 1H), 4.16 (t, <i>J</i> = 5.8 Hz, 2H), 2.83 (t, <i>J</i> = 5.8 Hz, 2H), 2.62–2.50 (m, 4H), 1.80–1.64 (m, 4H), 1.32 (s, 9H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>35</sub>N<sub>7</sub>O<sub>4</sub>: 557.64; found, 558.6(M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>30</sub>H<sub>36</sub>N<sub>7</sub>O<sub>4</sub>: 558.2823; found, 558.2841 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 42.79 min, 95.6%.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-[3-4-{[(5-(<i>tert</i>-Butyl)-1,2-oxazol-3-yl)carbamoyl]amino}phenyl]-1<i>H</i>-pyrazol-5-yl]-4-(3-(pyrrolidin-1-yl)propoxy]benzamide (<b>5j</b>)</h3><div class="NLM_p last">Mp 172–174 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 10.65 (s, 1H), 9.77 (s, 1H), 9.61 (s, 1H), 7.98 (d, <i>J</i> = 9.3 Hz, 2H), 7.64 (d, <i>J</i> = 8.4 Hz, 2H), 7.59 (d, <i>J</i> = 8.4 Hz, 2H), 6.99 (d, <i>J</i> = 9.0 Hz, 2H), 6.86 (bs, 1H), 6.48 (s, 1H), 4.08 (t, <i>J</i> = 6.2 Hz, 2H), 3.10–2.60 (m, 6H), 2.03 (t, <i>J</i> = 7.1 Hz, 2H), 1.85–1.60 (m, 4H), 1.25 (s, 9H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>37</sub>N<sub>7</sub>O<sub>4</sub>: 571.29; found, 572.1(M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 24.24 min, 95.6%.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>1-(3-4-[([5-(<i>tert</i>-Butyl)-3-isoxazolyl]aminocarbonyl)amino]-3-methylphenyl-1<i>H</i>-5-pyrazolyl)-4-(2-morpholinoethoxy)benzamide (<b>5k</b>)</h3><div class="NLM_p last">Mp 258–260 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 12.77 (s, 1H), 10.69 (s, 1H), 9.98 (s, 1H), 8.38 (s, 1H), 7.99 (t, <i>J</i> = 9.6 Hz, 3H), 7.61–7.55 (m, 2H), 7.04 (d, <i>J</i> = 9.0 Hz, 2H), 6.91 (s, 1H), 6.48 (s, 1H), 4.16 (t, <i>J</i> = 5.7 Hz, 2H), 3.58 (t, <i>J</i> = 4.5 Hz, 4H), 2.71 (t, <i>J</i> = 5.7 Hz, 2H), 2.50–2.46 (m, 4H), 2.30 (s 3H), 1.30 (s, 9H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>37</sub>N<sub>7</sub>O<sub>5</sub>: 587.29; found, 588.4 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>31</sub>H<sub>38</sub>N<sub>7</sub>O<sub>5</sub>: 588.2934; found, 588.2926 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 23.60 min, 98.0%.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>1-(3-4-[([5-(<i>tert</i>-Butyl)-3-isoxazolyl]aminocarbonyl)amino]phenyl-1<i>H</i>-5-pyrazolyl)-4-(4-methylpiperazino)benzamide (<b>5l</b>)</h3><div class="NLM_p last">Mp 332–334 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 12.74 (s, 1H), 10.51 (s, 1H), 9.58 (s, 1H), 8.99 (s, 1H), 7.92 (d, <i>J</i> = 9.2 Hz, 2H), 7.69 (d, <i>J</i> = 8.4 Hz, 2H), 7.53 (d, <i>J</i> = 8.8 Hz, 2H), 6.99–6.92 (m, 3H), 6.53 (s, 1H), 3.29–3.27 (m, 4H), 2.47–2.43 (m, 4H), 2.23 (s, 3H), 1.27 (s, 9H). MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub>: 542.28; found, 543.3 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>29</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub>: 543.2827; found, 543.2832 (M + H<sup>+</sup>). HPLC: <i>t</i><sub>R</sub> = 22.70 min, 99.9%.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00106">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00106" class="ext-link">10.1021/acs.jmedchem.6b00106</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Binding kinetics analysis of <b>5a</b>, <b>4</b>, and crizotinib; density maps of <b>5a</b>, <b>4</b>, and <b>5d</b> in the active site of ALK; docking position of the designed ALK inhibitor in the binding site of ALK (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_001.pdf">jm6b00106_si_001.pdf (891.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_002.csv">jm6b00106_si_002.csv (1.15 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUG">5IUG</a> (ALK/<b>5a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUH">5IUH</a> (ALK/<b>5d</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUI">5IUI</a> (ALK/<b>4</b>).</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00106" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weir-Torn Jiaang</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#aed9dac4c7cfcfc0c9eec0c6dcc780c1dcc980dad9"><span class="__cf_email__" data-cfemail="a2d5d6c8cbc3c3ccc5e2cccad0cb8ccdd0c58cd6d5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Su-Ying Wu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#582b2d2131363f1836302a3176372a3f762c2f"><span class="__cf_email__" data-cfemail="9deee8e4f4f3faddf3f5eff4b3f2effab3e9ea">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chih-Hsiang Tu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span>; 
    <span class="hlFld-Affiliation affiliation">Institute
of Bioinformatics and Structural Biology, National Tsing Hua University, 101, Sect. 2, Guangfu Road, Hsinchu 300, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen-Hsing Lin</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Hui Peng</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsu Hsu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian-Sung Wu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Yu Chang</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng-Tai Lu</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping-Chiang Lyu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Bioinformatics and Structural Biology, National Tsing Hua University, 101, Sect. 2, Guangfu Road, Hsinchu 300, Taiwan, ROC</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chuan Shih</span> - <span class="hlFld-Affiliation affiliation">Institute of Biotechnology
and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.-H. L. and Y.-H. P. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="notes-4"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National Health Research Institute, Taiwan, ROC, and National Science Council (NSC Grant 104-2325-B-400-003). We thank the technical services provided by the “Synchrotron Radiation Protein Crystallography Facility of the National Core Facility Program for Biotechnology, Ministry of Science and Technology” and the “National Synchrotron Radiation Research Center”, a national user facility supported by the Ministry of Science and Technology, Taiwan, ROC</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i36" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i36"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i37" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i37"> Abbreviations Used</h2><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">NHL</td><td class="NLM_def"><p class="first last">non-Hodgkin’s lymphoma</p></td></tr><tr><td class="NLM_term">CARS</td><td class="NLM_def"><p class="first last">cysteinyl-tRNA synthetase</p></td></tr><tr><td class="NLM_term">IMT</td><td class="NLM_def"><p class="first last">inflammatory myofibroblastic tumor</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule associated protein like 4</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung carcinoma</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp-Phe-Gly</p></td></tr><tr><td class="NLM_term">HRD</td><td class="NLM_def"><p class="first last">His-Arg-Asp</p></td></tr><tr><td class="NLM_term">JM</td><td class="NLM_def"><p class="first last">juxtamembrane</p></td></tr><tr><td class="NLM_term">A-loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">P-loop</td><td class="NLM_def"><p class="first last">phosphate-binding loop</p></td></tr><tr><td class="NLM_term">R-spine</td><td class="NLM_def"><p class="first last">regulatory spine</p></td></tr><tr><td class="NLM_term">C-spine</td><td class="NLM_def"><p class="first last">catalytic spine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0lgbDw2i0YUoAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hallberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, R. H.</span><span> </span><span class="NLM_article-title">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/nrc3580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnrc3580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24060861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=685-700&author=B.+Hallbergauthor=R.+H.+Palmer&title=Mechanistic+insight+into+ALK+receptor+tyrosine+kinase+in+human+cancer+biology&doi=10.1038%2Fnrc3580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span></div><div class="casAuthors">Hallberg, Bengt; Palmer, Ruth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">685-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC).  The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK.  In this review, we discuss our current understanding of ALK function in human cancer and the implications for tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADI-N0ZBEr7Vg90H21EOLACvtfcHk0lhCNcI5dhTpmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP&md5=fab66b12114ca01348df4ca08d3b3e4e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3580%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DMechanistic%2520insight%2520into%2520ALK%2520receptor%2520tyrosine%2520kinase%2520in%2520human%2520cancer%2520biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fnrc3580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0lhCNcI5dhTpmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">New strategies for treatment of ALK-rearranged non-small cell lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7213</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F1078-0432.CCR-11-1404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22010214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7213-7218&author=T.+Sasakiauthor=P.+A.+Janne&title=New+strategies+for+treatment+of+ALK-rearranged+non-small+cell+lung+cancers&doi=10.1158%2F1078-0432.CCR-11-1404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers</span></div><div class="casAuthors">Sasaki, Takaaki; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7213-7218</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The identification of oncogenic alterations in subsets of patients with non-small cell lung cancer (NSCLC) is transforming clin. care.  Genomic rearrangements in anaplastic lymphoma kinase (ALK) are detected in 3% to 7% of patients with NSCLC.  The ALK tyrosine kinase inhibitor crizotinib has demonstrated clin. efficacy in ALK-rearranged NSCLC patients and was recently approved by the U.S.  Food and Drug Administration.  Crizotinib is currently under addnl. phase III clin. development as both initial and second-line therapy for advanced ALK-rearranged NSCLC.  However, new challenges in the diagnosis and treatment of this subset of NSCLC have emerged, including the need to det. the most effective means of diagnosing ALK-rearranged NSCLC and the emergence of acquired drug resistance to crizotinib.  In this review, we discuss current strategies for treatment and diagnosis, as well as the current knowledge about mechanisms of acquired resistance to crizotinib.  Finally, we discuss the strategies that are underway to clin. overcome acquired drug resistance.  Clin Cancer Res; 17(23); 7213-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocg76jJ18-jrVg90H21EOLACvtfcHk0lhCNcI5dhTpmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrzP&md5=adc9f7969982dbcd1ad9b8c2c639ef0e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1404%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNew%2520strategies%2520for%2520treatment%2520of%2520ALK-rearranged%2520non-small%2520cell%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7213%26epage%3D7218%26doi%3D10.1158%2F1078-0432.CCR-11-1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lg2fxIUhKJzbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lg2fxIUhKJzbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span><span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.+Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulf+onyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0lg2fxIUhKJzbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.%2BQ.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulf%2520onyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konagai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fushiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakagami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+selective+anaplastic+lymphoma+receptor+tyrosine+kinase+inhibitor+ASP3026+induces+tumor+regression+and+prolongs+survival+in+non-small+cell+lung+cancer+model+mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0lhEdXPY1Stjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520selective%2520anaplastic%2520lymphoma%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ASP3026%2520induces%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520non-small%2520cell%2520lung%2520cancer%2520model%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giudici, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F1541-7786.MCR-14-0157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=25421750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlChtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=775-783&author=M.+Cecconauthor=L.+Mologniauthor=G.+Giudiciauthor=R.+Piazzaauthor=A.+Pirolaauthor=D.+Fontanaauthor=C.+Gambacorti-Passerini&title=Treatment+efficacy+and+resistance+mechanisms+using+the+second-generation+ALK+inhibitor+AP26113+in+human+NPM-ALK-positive+anaplastic+large+cell+lymphoma&doi=10.1158%2F1541-7786.MCR-14-0157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma</span></div><div class="casAuthors">Ceccon, M.; Mologni, L.; Giudici, G.; Piazza, R.; Pirola, A.; Fontana, D.; Gambacorti-Passerini, C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">775-783</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ALK is a tyrosine kinase receptor involved in a broad range of solid and hematol. tumors.  Among 70% to 80% of ALK+ anaplastic large cell lymphomas (ALCL) are caused by the aberrant oncogenic fusion protein NPM-ALK.  Crizotinib was the first clin. relevant ALK inhibitor, now approved for the treatment of late-stage and metastatic cases of lung cancer.  However, patients frequently develop drug resistance to Crizotinib, mainly due to the appearance of point mutations located in the ALK kinase domain.  Fortunately, other inhibitors are available and in clin. trial, suggesting the potential for second-line therapies to overcome Crizotinib resistance.  This study focuses on the ongoing phase I/II trial small-mol. tyrosine kinase inhibitor (TKI) AP26113, by Ariad Pharmaceuticals, which targets both ALK and EGFR.  Two NPM-ALK+ human cell lines, KARPAS-299 and SUP-M2, were grown in the presence of increasing concns. of AP26113, and eight lines were selected that demonstrated resistance.  All lines show IC50 values higher (130 to 1,000-fold) than the parental line.  Mechanistically, KARPAS-299 populations resistant to AP26113 show NPM-ALK overexpression, whereas SUP-M2-resistant cells harbor several point mutations spanning the entire ALK kinase domain.  In particular, amino acid substitutions: L1196M, S1206C, the double F1174V+L1198F and L1122V+L1196M mutations were identified.  The knowledge of the possible appearance of new clin. relevant mechanisms of drug resistance is a useful tool for the management of new TKI-resistant cases.  Implications: This work defines reliable ALCL model systems of AP26113 resistance and provides a valuable tool in the management of all cases of relapse upon NPM-ALK-targeted therapy.  Mol Cancer Res; 13(4); 775-83. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoejoukJP2mhbVg90H21EOLACvtfcHk0lhEdXPY1Stjjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlChtrk%253D&md5=3922eb8e16f1748fd4b1e5f932df4ae4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0157%26sid%3Dliteratum%253Aachs%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DGiudici%26aufirst%3DG.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DPirola%26aufirst%3DA.%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DTreatment%2520efficacy%2520and%2520resistance%2520mechanisms%2520using%2520the%2520second-generation%2520ALK%2520inhibitor%2520AP26113%2520in%2520human%2520NPM-ALK-positive%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26spage%3D775%26epage%3D783%26doi%3D10.1158%2F1541-7786.MCR-14-0157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lh_vYOpA64-MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Rothenstein, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letarte, N.</span><span> </span><span class="NLM_article-title">Managing treatment-related adverse events associated with Alk inhibitors</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.3747/co.21.1740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.3747%2Fco.21.1740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24523601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A280%3ADC%252BC2cvkslynsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=19-26&author=J.+M.+Rothensteinauthor=N.+Letarte&title=Managing+treatment-related+adverse+events+associated+with+Alk+inhibitors&doi=10.3747%2Fco.21.1740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Managing treatment-related adverse events associated with Alk inhibitors</span></div><div class="casAuthors">Rothenstein J M; Letarte N</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology (Toronto, Ont.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-26</span>
        ISSN:<span class="NLM_cas:issn">1198-0052</span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (nsclcs).  Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of patients.  Because of the prevalence of nsclc, ALK-positive patients represent an important example of the paradigm for personalized medicine.  Although Alk inhibitors such as crizotinib are well tolerated, there is a potential for adverse events to occur.  Proactive monitoring, treatment, and education concerning those adverse events will help to optimize the therapeutic index of the drugs.  The present review summarizes the management of treatment-related adverse events that can arise with Alk inhibitors such as crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThWqYfhR02EYHWj6b1v8uTfW6udTcc2eY3y9AtWTWtI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvkslynsg%253D%253D&md5=5644f6915b4324fcf3abf119e7de6456</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3747%2Fco.21.1740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.21.1740%26sid%3Dliteratum%253Aachs%26aulast%3DRothenstein%26aufirst%3DJ.%2BM.%26aulast%3DLetarte%26aufirst%3DN.%26atitle%3DManaging%2520treatment-related%2520adverse%2520events%2520associated%2520with%2520Alk%2520inhibitors%26jtitle%3DCurr.%2520Oncol.%26date%3D2014%26volume%3D21%26spage%3D19%26epage%3D26%26doi%3D10.3747%2Fco.21.1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1019</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70344-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS1470-2045%2812%2970344-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22954507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1011-1019&author=D.+R.+Camidgeauthor=Y.+J.+Bangauthor=E.+L.+Kwakauthor=A.+J.+Iafrateauthor=M.+Varella-Garciaauthor=S.+B.+Foxauthor=G.+J.+Rielyauthor=B.+Solomonauthor=S.+H.+I.+Ouauthor=D.+W.+Kimauthor=R.+Salgiaauthor=P.+Fidiasauthor=J.+A.+Engelmanauthor=L.+Gandhiauthor=P.+A.+Janneauthor=D.+B.+Costaauthor=G.+I.+Shapiroauthor=P.+LoRussoauthor=K.+Ruffnerauthor=P.+Stephensonauthor=Y.+Y.+Tangauthor=K.+Wilnerauthor=J.+W.+Clarkauthor=A.+T.+Shaw&title=Activity+and+safety+of+crizotinib+in+patients+with+ALK-positive+non-small-cell+lung+cancer%3A+updated+results+from+a+phase+1+study&doi=10.1016%2FS1470-2045%2812%2970344-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</span></div><div class="casAuthors">Camidge, D. Ross; Bang, Yung-Jue; Kwak, Eunice L.; Iafrate, A. John; Varella-Garcia, Marileila; Fox, Stephen B.; Riely, Gregory J.; Solomon, Benjamin; Ou, Sai-Hong I.; Kim, Dong-Wan; Salgia, Ravi; Fidias, Panagiotis; Engelman, Jeffrey A.; Gandhi, Leena; Jaenne, Pasi A.; Costa, Daniel B.; Shapiro, Geoffrey I.; LoRusso, Patricia; Ruffner, Katherine; Stephenson, Patricia; Tang, Yiyun; Wilner, Keith; Clark, Jeffrey W.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1011-1019</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).  We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study.  Methods: In this phase 1 study, patients with ALK-pos. stage III or IV NSCLC received oral crizotinib 250 mg twice daily in 28-day cycles.  Endpoints included tumor responses, duration of response, time to tumor response, progression-free survival (PFS), overall survival at 6 and 12 mo, and detn. of the safety and tolerability and characterization of the plasma pharmacokinetic profile of crizotinib after oral administration.  Responses were analyzed in evaluable patients and PFS and safety were analyzed in all patients.  This study is registered with ClinicalTrials.gov, no. NCT00585195.  Findings: Between Aug 27, 2008, and June 1, 2011, 149 ALK-pos. patients were enrolled, 143 of whom were included in the response-evaluable population. 87 of 143 patients had an objective response (60·8%, 95% CI 52·3-68·9), including three complete responses and 84 partial responses.  Median time to first documented objective response was 7·9 wk (range 2·1-39·6) and median duration of response was 49·1 wk (95% CI 39·3-75·4).  The response rate seemed to be largely independent of age, sex, performance status, or line of treatment.  Median PFS was 9·7 mo (95% CI 7·7-12·8).  Median overall survival data are not yet mature, but estd. overall survival at 6 and 12 mo was 87·9% (95% CI 81·3-92·3) and 74·8% (66·4-81·5), resp. 39 patients continued to receive crizotinib for more than 2 wk after progression because of perceived ongoing clin. benefit from the drug (12 for at least 6 mo from the time of their initial investigator-defined disease progression).  Overall, 144 (97%) of 149 patients experienced treatment-related adverse events, which were mostly grade 1 or 2.  The most common adverse events were visual effects, nausea, diarrhoea, constipation, vomiting, and peripheral edema.  The most common treatment-related grade 3 or 4 adverse events were neutropenia (n=9), raised alanine aminotransferase (n=6), hypophosphatemia (n=6), and lymphopenia (n=6).  Interpretation: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-pos. NSCLC.  There seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.  Funding: Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNr3aI1rrjmbVg90H21EOLACvtfcHk0lgEL2jKvQwr3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E&md5=bd3aec44b197ee2f4c9d49ea540a672f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970344-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970344-3%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DRuffner%26aufirst%3DK.%26aulast%3DStephenson%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%2BY.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DActivity%2520and%2520safety%2520of%2520crizotinib%2520in%2520patients%2520with%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%253A%2520updated%2520results%2520from%2520a%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D1011%26epage%3D1019%26doi%3D10.1016%2FS1470-2045%2812%2970344-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, L. Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, D. S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vansteenkiste, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, Y. Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boral, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">8010</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1200%2FJCO.2012.44.5353" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=8010&author=A.+T.+Shawauthor=R.+Mehraauthor=D.+W.+Kimauthor=E.+Felipauthor=L.+Q.+M.+Chowauthor=D.+R.+Camidgeauthor=D.+S.+W.+Tanauthor=J.+F.+Vansteenkisteauthor=S.+Sharmaauthor=T.+De+Pasauthor=J.+Wolfauthor=R.+Katayamaauthor=Y.+Y.+Y.+Lauauthor=M.+Goldwasserauthor=A.+Boralauthor=J.+A.+Engelman&title=Clinical+activity+of+the+ALK+inhibitor+LDK378+in+advanced%2C+ALK-positive+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.5353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.5353%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DChow%26aufirst%3DL.%2BQ.%2BM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DVansteenkiste%26aufirst%3DJ.%2BF.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLau%26aufirst%3DY.%2BY.%2BY.%26aulast%3DGoldwasser%26aufirst%3DM.%26aulast%3DBoral%26aufirst%3DA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DClinical%2520activity%2520of%2520the%2520ALK%2520inhibitor%2520LDK378%2520in%2520advanced%252C%2520ALK-positive%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D8010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshioka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70142-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS1470-2045%2813%2970142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23639470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=590-598&author=T.+Setoauthor=K.+Kiuraauthor=M.+Nishioauthor=K.+Nakagawaauthor=M.+Maemondoauthor=A.+Inoueauthor=T.+Hidaauthor=N.+Yamamotoauthor=H.+Yoshiokaauthor=M.+Haradaauthor=Y.+Oheauthor=N.+Nogamiauthor=K.+Takeuchiauthor=T.+Shimadaauthor=T.+Tanakaauthor=T.+Tamura&title=CH5424802+%28RO5424802%29+for+patients+with+ALK-rearranged+advanced+non-small-cell+lung+cancer+%28AF-001JP+study%29%3A+a+single-arm%2C+open-label%2C+phase+1%E2%80%932+study&doi=10.1016%2FS1470-2045%2813%2970142-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study</span></div><div class="casAuthors">Seto, Takashi; Kiura, Katsuyuki; Nishio, Makoto; Nakagawa, Kazuhiko; Maemondo, Makoto; Inoue, Akira; Hida, Toyoaki; Yamamoto, Nobuyuki; Yoshioka, Hiroshige; Harada, Masao; Ohe, Yuichiro; Nogami, Naoyuki; Takeuchi, Kengo; Shimada, Tadashi; Tanaka, Tomohiro; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">590-598</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available ALK inhibitor.  In this multicenter, single-arm, open-label, phase 1-2 study of CH5424802, we recruited ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC from 13 hospitals in Japan.  In the phase 1 portion of the study, patients received CH5424802 orally twice daily by dose escalation.  The primary endpoints of the phase 1 were dose limiting toxicity (DLT), max. tolerated dose (MTD), and pharmacokinetic parameters.  In the phase 2 portion of the study, patients received CH5424802 at the recommended dose identified in the phase 1 portion of the study orally twice a day.  The primary endpoint of the phase 2 was the proportion of patients who had an objective response.  Treatment was continued in 21-day cycles until disease progression, intolerable adverse events, or withdrawal of consent.  The anal. was done by intent to treat.  This study is registered with the Japan Pharmaceutical Information Center, no. JapicCTI-101264.  Patients were enrolled between Sept 10, 2010, and Apr. 18, 2012.  The data cutoff date was July 31, 2012.  In the phase 1 portion, 24 patients were treated at doses of 20-300 mg twice daily.  No DLTs or adverse events of grade 4 were noted up to the highest dose; thus 300 mg twice daily was the recommended phase 2 dose.  In the phase 2 portion of the study, 46 patients were treated with the recommended dose, of whom 43 achieved an objective response (93·5%, 95% CI 82·1-98·6) including two complete responses (4·3%, 0·5-14·8) and 41 partial responses (89·1%, 76·4-96·4).  Treatment-related adverse events of grade 3 were recorded in 12 (26%) of 46 patients, including two patients each experiencing decreased neutrophil count and increased blood creatine phosphokinase.  Serious adverse events occurred in five patients (11%).  No grade 4 adverse events or deaths were reported.  The study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.  CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC.  Chugai Pharmaceutical Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnUGKVRfsBbVg90H21EOLACvtfcHk0lgEL2jKvQwr3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D&md5=489043eede3a37bb8ce76c6f1dc0296d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970142-6%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DCH5424802%2520%2528RO5424802%2529%2520for%2520patients%2520with%2520ALK-rearranged%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528AF-001JP%2520study%2529%253A%2520a%2520single-arm%252C%2520open-label%252C%2520phase%25201%25E2%2580%25932%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D590%26epage%3D598%26doi%3D10.1016%2FS1470-2045%2813%2970142-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Blanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Type II kinase inhibitors: an opportunity in cancer for rational design</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.2174/1871520611313050008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+kinase+inhibitors%3A+an+opportunity+in+cancer+for+rational+design&doi=10.2174%2F1871520611313050008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0licypCmtWZJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520kinase%2520inhibitors%253A%2520an%2520opportunity%2520in%2520cancer%2520for%2520rational%2520design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747%26doi%3D10.2174%2F1871520611313050008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0licypCmtWZJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0licypCmtWZJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span><span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0licypCmtWZJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staehle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, C. C.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and pharmacodynamics of single doses of an oral p38 MAP kinase inhibitor (BIRB 796 BS) in healthy human males - a placebo-controlled, randomised study, double blinded at each dose level</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">S67</span><span class="NLM_x">–</span> <span class="NLM_lpage">S67</span><span class="refDoi"> DOI: 10.1016/S0091-6749(02)81294-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS0091-6749%2802%2981294-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=S67-S67&author=A.+Guptaauthor=C.+L.+Yongauthor=J.+B.+Madwedauthor=H.+Staehleauthor=C.+C.+Wood&title=Safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+single+doses+of+an+oral+p38+MAP+kinase+inhibitor+%28BIRB+796+BS%29+in+healthy+human+males+-+a+placebo-controlled%2C+randomised+study%2C+double+blinded+at+each+dose+level&doi=10.1016%2FS0091-6749%2802%2981294-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0091-6749%2802%2981294-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-6749%252802%252981294-5%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DMadwed%26aufirst%3DJ.%2BB.%26aulast%3DStaehle%26aufirst%3DH.%26aulast%3DWood%26aufirst%3DC.%2BC.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520single%2520doses%2520of%2520an%2520oral%2520p38%2520MAP%2520kinase%2520inhibitor%2520%2528BIRB%2520796%2520BS%2529%2520in%2520healthy%2520human%2520males%2520-%2520a%2520placebo-controlled%252C%2520randomised%2520study%252C%2520double%2520blinded%2520at%2520each%2520dose%2520level%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D109%26spage%3DS67%26epage%3DS67%26doi%3D10.1016%2FS0091-6749%2802%2981294-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobburu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">U, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staten, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=12006504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=935-942&author=M.+H.+Cohenauthor=G.+Williamsauthor=J.+R.+Johnsonauthor=J.+Duanauthor=J.+Gobburuauthor=A.+Rahmanauthor=K.+Bensonauthor=J.+Leightonauthor=S.+K.+Kimauthor=R.+Woodauthor=M.+Rothmannauthor=G.+Chenauthor=K.+M.+Uauthor=A.+M.+Statenauthor=R.+Pazdur&title=Approval+summary+for+imatinib+mesylate+capsules+in+the+treatment+of+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant; Johnson, John R.; Duan, John; Gobburu, Jogarao; Rahman, Atiqur; Benson, Kimberly; Leighton, John; Kim, Sung K.; Wood, Rebecca; Rothmann, Mark; Chen, Gang; Maung U., Khin; Staten, Ann M.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis.  Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines.  In this report, we describe the preclin. profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.  Chem. manufg. and controls, animal toxicol., and biopharmaceutical data are described.  Results of Phase I and Phase II clin. studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN-α (CML-CP) are summarized.  The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.  Toxicol. studies in the rat, dog, and monkey show the hematol., renal, and hepatobiliary toxicity of imatinib.  Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability.  The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approx. 18 and 40 h, resp.  Approx. 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine.  Cytochrome P 450 3A4 is the main enzyme responsible for imatinib metab.  Phase I and II clin. studies were conducted.  The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day.  Dose-limiting toxicity was not obsd.  The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients.  CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day, imatinib.  Primary study endpoints were cytogenetic response rate (CML-CP) and hematol. response rate (CML-AP and CML-BC).  The cytogenetic response rate for CML-CP patients was 49%.  The hematol. response rate of CML-AP and CML-BC patients was 63 and 26%, resp.  The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea.  Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).  On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufd. and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clin. settings: CML-BC, CML-AP, and CML-CP.  This report summarizes the Food and Drug Administration's review of the New Drug Application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2majxsiqE3LVg90H21EOLACvtfcHk0lh7ggDmsD3i0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D&md5=8820d9e1126524a6762242f68262ab86</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DWood%26aufirst%3DR.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DU%26aufirst%3DK.%2BM.%26aulast%3DStaten%26aufirst%3DA.%2BM.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520imatinib%2520mesylate%2520capsules%2520in%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D935%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kufareva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span> </span><span class="NLM_article-title">Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7921</span><span class="NLM_x">–</span> <span class="NLM_lpage">7932</span><span class="refDoi"> DOI: 10.1021/jm8010299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7921-7932&author=I.+Kufarevaauthor=R.+Abagyan&title=Type-II+kinase+inhibitor+docking%2C+screening%2C+and+profiling+using+modified+structures+of+active+kinase+states&doi=10.1021%2Fjm8010299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span></div><div class="casAuthors">Kufareva, Irina; Abagyan, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7921-7932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type-II kinase inhibitors represent a class of chems. that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site.  These compds. are often more specific than those that target active DFG-in kinase conformations.  Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable.  We present a computational protocol for converting multiple available DFG-in structures of various kinases (∼70% of mammalian structural kinome) into accurate and specific models of their type-II bound state.  The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compd. pose prediction, screening, and in silico activity profiling.  Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific mols. targeting inactive kinase states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp699dzZf5YRLVg90H21EOLACvtfcHk0lh7ggDmsD3i0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK&md5=64fb7b9f789940dd61c68015341af4a6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm8010299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010299%26sid%3Dliteratum%253Aachs%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DType-II%2520kinase%2520inhibitor%2520docking%252C%2520screening%252C%2520and%2520profiling%2520using%2520modified%2520structures%2520of%2520active%2520kinase%2520states%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7921%26epage%3D7932%26doi%3D10.1021%2Fjm8010299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emkey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span> </span><span class="NLM_article-title">The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">37447</span><span class="NLM_x">–</span> <span class="NLM_lpage">37457</span><span class="refDoi"> DOI: 10.1074/jbc.M112.391425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1074%2Fjbc.M112.391425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22932897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=37447-37457&author=L.+F.+Epsteinauthor=H.+Chenauthor=R.+Emkeyauthor=D.+A.+Whittington&title=The+R1275Q+neuroblastoma+mutant+and+certain+ATP-competitive+inhibitors+stabilize+alternative+activation+loop+conformations+of+anaplastic+lymphoma+kinase&doi=10.1074%2Fjbc.M112.391425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Epstein, Linda F.; Chen, Hao; Emkey, Renee; Whittington, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37447-37457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that, when genetically altered by mutation, amplification, chromosomal translocation or inversion, has been shown to play an oncogenic role in certain cancers.  Small mol. inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.  In neuroblastoma, activating point mutations in the ALK kinase domain can drive disease progression, with the two most common mutations being F1174L and R1275Q.  We report here crystal structures of the ALK kinase domain contg. the F1174L and R1275Q mutations.  Also included are crystal structures of ALK in complex with novel small mol. ALK inhibitors, including a classic type II inhibitor, that stabilize previously unobserved conformations of the ALK activation loop.  Collectively, these structures illustrate a different series of activation loop conformations than has been obsd. in previous ALK crystal structures and provide insight into the activating nature of the R1275Q mutation.  The novel active site topologies presented here may also aid the structure-based drug design of a new generation of ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0rQKncKYwgrVg90H21EOLACvtfcHk0lh7ggDmsD3i0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K&md5=ac3a068a4837dfb1d63d54826d2b4564</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.391425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.391425%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26atitle%3DThe%2520R1275Q%2520neuroblastoma%2520mutant%2520and%2520certain%2520ATP-competitive%2520inhibitors%2520stabilize%2520alternative%2520activation%2520loop%2520conformations%2520of%2520anaplastic%2520lymphoma%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D37447%26epage%3D37457%26doi%3D10.1074%2Fjbc.M112.391425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W. T.</span><span> </span><span class="NLM_article-title">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2856</span><span class="NLM_x">–</span> <span class="NLM_lpage">2867</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmc.2013.03.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23618709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2856-2867&author=W.+H.+Linauthor=J.+T.+Hsuauthor=S.+Y.+Hsiehauthor=C.+T.+Chenauthor=J.+S.+Songauthor=S.+C.+Yenauthor=T.+Hsuauthor=C.+T.+Luauthor=C.+H.+Chenauthor=L.+H.+Chouauthor=Y.+N.+Yangauthor=C.+H.+Chiuauthor=C.+P.+Chenauthor=Y.+J.+Tsengauthor=K.+J.+Yenauthor=C.+F.+Yehauthor=Y.+S.+Chaoauthor=T.+K.+Yehauthor=W.+T.+Jiaang&title=Discovery+of+3-phenyl-1H-5-pyrazolylamine+derivatives+containing+a+urea+pharmacophore+as+potent+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmc.2013.03.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Lin, Wen-Hsing; Hsu, John T.-A.; Hsieh, Shu-Yi; Chen, Chiung-Tong; Song, Jen-Shin; Yen, Shih-Chieh; Hsu, Tsu; Lu, Cheng-Tai; Chen, Chun-Hwa; Chou, Ling-Hui; Yang, Yung-Ning; Chiu, Ching-Hui; Chen, Ching-Ping; Tseng, Ya-Ju; Yen, Kuei-Jung; Yeh, Ching-Fang; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2856-2867</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preclin. investigations and early clin. trials suggest that FLT3 inhibitors are a viable therapy for acute myeloid leukemia.  However, early clin. data have been underwhelming due to incomplete inhibition of FLT3.  The authors have developed 3-phenyl-1H-5-pyrazolylamine as an efficient template for kinase inhibitors.  Structure-activity relationships led to the discovery of sulfonamide, carbamate and urea series of FLT3 inhibitors.  Previous studies showed that the sulfonamide and carbamate series were potent and selective FLT3 inhibitors with good in vivo efficacy.  Herein, the authors describe the urea series, which the authors found to be potent inhibitors of FLT3 and VEGFR2.  Some inhibited growth of FLT3-mutated MOLM-13 cells more strongly than the FLT3 inhibitors sorafenib and ABT-869.  In preliminary in vivo toxicity studies of the four most active compds., N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide was found to be the least toxic.  A further in vivo efficacy study demonstrated that N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide achieved complete tumor regression in a higher proportion of MOLM-13 xenograft.  These results show that compd. N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide possesses improved pharmacol. and selectivity profiles and could be more effective than previously disclosed FLT3 inhibitors in the treatment of acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8nbO4pzTXbrVg90H21EOLACvtfcHk0lj5UDV18hNVvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D&md5=3b4f4323360170e8a7fbe763b79d3128</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.083%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BN.%26aulast%3DChiu%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DTseng%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DYeh%26aufirst%3DC.%2BF.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3DDiscovery%2520of%25203-phenyl-1H-5-pyrazolylamine%2520derivatives%2520containing%2520a%2520urea%2520pharmacophore%2520as%2520potent%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2856%26epage%3D2867%26doi%3D10.1016%2Fj.bmc.2013.03.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W. T.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4173</span><span class="NLM_x">–</span> <span class="NLM_lpage">4182</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmc.2011.06.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=4173-4182&author=W.+H.+Linauthor=S.+Y.+Hsiehauthor=S.+C.+Yenauthor=C.+T.+Chenauthor=T.+K.+Yehauthor=T.+Hsuauthor=C.+T.+Luauthor=C.+P.+Chenauthor=C.+W.+Chenauthor=L.+H.+Chouauthor=Y.+L.+Huangauthor=A.+H.+Chengauthor=Y.+I.+Changauthor=Y.+J.+Tsengauthor=K.+R.+Yenauthor=Y.+S.+Chaoauthor=J.+T.+Hsuauthor=W.+T.+Jiaang&title=Discovery+and+evaluation+of+3-phenyl-1H-5-pyrazolylamine-based+derivatives+as+potent%2C+selective+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmc.2011.06.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DChen%26aufirst%3DC.%2BW.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BI.%26aulast%3DTseng%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DK.%2BR.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25203-phenyl-1H-5-pyrazolylamine-based%2520derivatives%2520as%2520potent%252C%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D4173%26epage%3D4182%26doi%3D10.1016%2Fj.bmc.2011.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W. T.</span><span> </span><span class="NLM_article-title">3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4654</span><span class="NLM_x">–</span> <span class="NLM_lpage">4659</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmcl.2012.05.116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4654-4659&author=J.+T.+Hsuauthor=T.+K.+Yehauthor=S.+C.+Yenauthor=C.+T.+Chenauthor=S.+Y.+Hsiehauthor=T.+Hsuauthor=C.+T.+Luauthor=C.+H.+Chenauthor=L.+H.+Chouauthor=C.+H.+Chiuauthor=Y.+I.+Changauthor=Y.+J.+Tsengauthor=K.+R.+Yenauthor=Y.+S.+Chaoauthor=W.+H.+Linauthor=W.+T.+Jiaang&title=3-Phenyl-1H-5-pyrazolylamine-based+derivatives+as+potent+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmcl.2012.05.116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.116%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DChiu%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BI.%26aulast%3DTseng%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DK.%2BR.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3D3-Phenyl-1H-5-pyrazolylamine-based%2520derivatives%2520as%2520potent%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4654%26epage%3D4659%26doi%3D10.1016%2Fj.bmcl.2012.05.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Tan, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedtke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavunkel, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perumattam, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nashashibi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liclican, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almirez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugar, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">828</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmcl.2009.12.091" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=828-831&author=X.+F.+Tanauthor=R.+W.+Testerauthor=G.+R.+Luedtkeauthor=S.+Chakravartyauthor=B.+J.+Mavunkelauthor=J.+J.+Perumattamauthor=Q.+Luauthor=I.+Nashashibiauthor=J.+Jungauthor=J.+Huauthor=A.+Liclicanauthor=R.+Almirezauthor=J.+Taboraauthor=V.+Tranauthor=M.+Laneyauthor=D.+E.+Levyauthor=S.+Dugar&title=Design+and+synthesis+of+piperazine-indole+p38+alpha+MAP+kinase+inhibitors+with+improved+pharmacokinetic+profiles&doi=10.1016%2Fj.bmcl.2009.12.091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.091%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DX.%2BF.%26aulast%3DTester%26aufirst%3DR.%2BW.%26aulast%3DLuedtke%26aufirst%3DG.%2BR.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DMavunkel%26aufirst%3DB.%2BJ.%26aulast%3DPerumattam%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DNashashibi%26aufirst%3DI.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DAlmirez%26aufirst%3DR.%26aulast%3DTabora%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DV.%26aulast%3DLaney%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDugar%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520piperazine-indole%2520p38%2520alpha%2520MAP%2520kinase%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520profiles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D828%26epage%3D831%26doi%3D10.1016%2Fj.bmcl.2009.12.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span>MarvinSketch <a href="https://www.chemaxon.com/products/marvin/marvinsketch/" class="extLink">https://www.chemaxon.com/products/marvin/marvinsketch/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MarvinSketch+https%3A%2F%2Fwww.chemaxon.com%2Fproducts%2Fmarvin%2Fmarvinsketch%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Donella-Deana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunby, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrarese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tartari, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, L. A.</span><span> </span><span class="NLM_article-title">Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">8533</span><span class="NLM_x">–</span> <span class="NLM_lpage">8542</span><span class="refDoi"> DOI: 10.1021/bi0472954</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0472954" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=8533-8542&author=A.+Donella-Deanaauthor=O.+Marinauthor=L.+Cesaroauthor=R.+H.+Gunbyauthor=A.+Ferrareseauthor=A.+M.+Colucciaauthor=C.+J.+Tartariauthor=L.+Mologniauthor=L.+Scapozzaauthor=C.+Gambacorti-Passeriniauthor=L.+A.+Pinna&title=Unique+substrate+specificity+of+anaplastic+lymphoma+kinase+%28ALK%29%3A+development+of+phosphoacceptor+peptides+for+the+assay+of+ALK+activity&doi=10.1021%2Fbi0472954"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi0472954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0472954%26sid%3Dliteratum%253Aachs%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DMarin%26aufirst%3DO.%26aulast%3DCesaro%26aufirst%3DL.%26aulast%3DGunby%26aufirst%3DR.%2BH.%26aulast%3DFerrarese%26aufirst%3DA.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DTartari%26aufirst%3DC.%2BJ.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DUnique%2520substrate%2520specificity%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520development%2520of%2520phosphoacceptor%2520peptides%2520for%2520the%2520assay%2520of%2520ALK%2520activity%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D8533%26epage%3D8542%26doi%3D10.1021%2Fbi0472954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haste, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17783</span><span class="NLM_x">–</span> <span class="NLM_lpage">17788</span><span class="refDoi"> DOI: 10.1073/pnas.0607656103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1073%2Fpnas.0607656103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=17095602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17783-17788&author=A.+P.+Kornevauthor=N.+M.+Hasteauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=Surface+comparison+of+active+and+inactive+protein+kinases+identifies+a+conserved+activation+mechanism&doi=10.1073%2Fpnas.0607656103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span></div><div class="casAuthors">Kornev, Alexandr P.; Haste, Nina M.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17783-17788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The surface comparison of different serine-threonine and tyrosine kinases reveals a set of 30 residues whose spatial positions are highly conserved.  The comparison between active and inactive conformations identified the residues whose positions are the most sensitive to activation.  Based on these results, we propose a model of protein kinase activation.  This model explains how the presence of a phosphate group in the activation loop dets. the position of the catalytically important aspartate in the Asp-Phe-Gly (DFG) motif.  According to the model, the most important feature of the activation is a "spine" formation that is dynamically assembled in all active kinases.  The spine is comprised of four hydrophobic residues that we detected in a set of 23 eukaryotic and prokaryotic kinases.  It spans the mol. and plays a coordinating role in activated kinases.  The spine is disordered in the inactive kinases and can explain how stabilization of the whole mol. is achieved upon phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwv4ByA5owH7Vg90H21EOLACvtfcHk0lhtbB3IgNPmMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ&md5=f474acffd8b17d8352ac9f6fc9bbbf8f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607656103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607656103%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHaste%26aufirst%3DN.%2BM.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DSurface%2520comparison%2520of%2520active%2520and%2520inactive%2520protein%2520kinases%2520identifies%2520a%2520conserved%2520activation%2520mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D17783%26epage%3D17788%26doi%3D10.1073%2Fpnas.0607656103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Jura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.molcel.2011.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.molcel.2011.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=21474065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=9-22&author=N.+Juraauthor=X.+Zhangauthor=N.+F.+Endresauthor=M.+A.+Seeligerauthor=T.+Schindlerauthor=J.+Kuriyan&title=Catalytic+control+in+the+EGF+receptor+and+its+connection+to+general+kinase+regulatory+mechanisms&doi=10.1016%2Fj.molcel.2011.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms</span></div><div class="casAuthors">Jura, Natalia; Zhang, Xue-Wu; Endres, Nicholas F.; Seeliger, Markus A.; Schindler, Thomas; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  In contrast to the active conformations of protein kinases, which are essentially the same for all kinases, inactive kinase conformations are structurally diverse.  Some inactive conformations are, however, obsd. repeatedly in different kinases, perhaps reflecting an important role in catalysis.  In this review, we analyze one of these recurring conformations, first identified in CDK and Src kinases, which turned out to be central to understanding of how kinase domain of the EGF receptor is activated.  This mechanism, which involves the stabilization of the active conformation of an α helix, has features in common with mechanisms operative in several other kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzfvk5EtYFJLVg90H21EOLACvtfcHk0lhBl2uhGaYDgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqt74%253D&md5=b891148117e35a5428fafee3a9efe06d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DJura%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DEndres%26aufirst%3DN.%2BF.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCatalytic%2520control%2520in%2520the%2520EGF%2520receptor%2520and%2520its%2520connection%2520to%2520general%2520kinase%2520regulatory%2520mechanisms%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D42%26spage%3D9%26epage%3D22%26doi%3D10.1016%2Fj.molcel.2011.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Protein kinases: evolution of dynamic regulatory proteins</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1016/j.tibs.2010.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.tibs.2010.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=20971646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=65-77&author=S.+S.+Taylorauthor=A.+P.+Kornev&title=Protein+kinases%3A+evolution+of+dynamic+regulatory+proteins&doi=10.1016%2Fj.tibs.2010.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases: evolution of dynamic regulatory proteins</span></div><div class="casAuthors">Taylor, Susan S.; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases have evolved as a family of highly dynamic mols. with a strictly organized internal architecture.  A single hydrophobic F-helix serves as a central scaffold for the assembly of the entire mol.  Two non-consecutive hydrophobic structures termed "spines" anchor all of the elements important for catalysis to the F-helix.  They make firm, but flexible, connections within the mol., providing a high level of internal dynamics of the protein kinase.  During the course of evolution, protein kinases developed a universal regulatory mechanism assocd. with a large activation segment that can be dynamically folded and unfolded in the course of cell functioning.  Protein kinases thus represent a unique, highly dynamic, and precisely regulated set of switches that control most biol. events in eukaryotic cells.  A comparison of 155 publicly available protein kinase structures of the human kinome, which includes 518 protein kinases divided into 7 major subfamilies, demonstrates a high level of structural plasticity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzcRXGPlBN7Vg90H21EOLACvtfcHk0lhBl2uhGaYDgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D&md5=f663148962d22944914e804e34fc947c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DProtein%2520kinases%253A%2520evolution%2520of%2520dynamic%2520regulatory%2520proteins%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2011%26volume%3D36%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.tibs.2010.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Palmer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernersson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, B.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: signalling in development and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">420</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1042/BJ20090387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1042%2FBJ20090387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+lymphoma+kinase%3A+signalling+in+development+and+disease&doi=10.1042%2FBJ20090387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1042%2FBJ20090387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090387%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520signalling%2520in%2520development%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361%26doi%3D10.1042%2FBJ20090387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L. C.</span><span> </span><span class="NLM_article-title">Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1074/jbc.M109.059758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1074%2Fjbc.M109.059758" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=95-103&author=P.+Wangauthor=F.+Wuauthor=Y.+Maauthor=L.+Liauthor=R.+Laiauthor=L.+C.+Young&title=Functional+characterization+of+the+kinase+activation+loop+in+nucleophosmin+%28NPM%29-anaplastic+lymphoma+kinase+%28ALK%29+using+tandem+affinity+purification+and+liquid+chromatography-mass+spectrometry&doi=10.1074%2Fjbc.M109.059758"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.059758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.059758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DL.%2BC.%26atitle%3DFunctional%2520characterization%2520of%2520the%2520kinase%2520activation%2520loop%2520in%2520nucleophosmin%2520%2528NPM%2529-anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520using%2520tandem%2520affinity%2520purification%2520and%2520liquid%2520chromatography-mass%2520spectrometry%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D95%26epage%3D103%26doi%3D10.1074%2Fjbc.M109.059758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Zorn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0121177</span><span class="refDoi"> DOI: 10.1371/journal.pone.0121177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1371%2Fjournal.pone.0121177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=25837374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0121177&author=J.+A.+Zornauthor=Q.+Wangauthor=E.+Fujimuraauthor=T.+Barrosauthor=J.+Kuriyan&title=Crystal+structure+of+the+FLT3+kinase+domain+bound+to+the+inhibitor+Quizartinib+%28AC220%29&doi=10.1371%2Fjournal.pone.0121177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)</span></div><div class="casAuthors">Zorn, Julie A.; Wang, Qi; Fujimura, Eric; Barros, Tiago; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0121177/1-e0121177/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3.  A small-mol. inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clin. trials appears promising for the treatment of AML.  Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib.  FLT3 with quizartinib bound adopts an "Abl-like"inactive conformation with the activation loop stabilized in the "DFG-out"orientation and folded back onto the kinase domain.  This conformation is similar to that obsd. for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop.  The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant obsd. in many AML patients.  This co-complex further provides a structural rationale for quizartinib-resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXAklBbZKP7Vg90H21EOLACvtfcHk0liwNOfq_ISdcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM&md5=d3c23bf8a8e242dd35e20e6e9b2de924</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121177%26sid%3Dliteratum%253Aachs%26aulast%3DZorn%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFujimura%26aufirst%3DE.%26aulast%3DBarros%26aufirst%3DT.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520FLT3%2520kinase%2520domain%2520bound%2520to%2520the%2520inhibitor%2520Quizartinib%2520%2528AC220%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0121177%26doi%3D10.1371%2Fjournal.pone.0121177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">31655</span><span class="NLM_x">–</span> <span class="NLM_lpage">31663</span><span class="refDoi"> DOI: 10.1074/jbc.M403319200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.+C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+STI-571+inhibition+of+c-Kit+tyrosine+kinase&doi=10.1074%2Fjbc.M403319200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Å resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Å crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0liwNOfq_ISdcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520STI-571%2520inhibition%2520of%2520c-Kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D31655%26epage%3D31663%26doi%3D10.1074%2Fjbc.M403319200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">18281</span><span class="NLM_x">–</span> <span class="NLM_lpage">18289</span><span class="refDoi"> DOI: 10.1073/pnas.1207759109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.+L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+conformations%2C+interactions%2C+and+properties+associated+with+drug+efficiency+and+clinical+performance+among+VEGFR+TK+inhibitors&doi=10.1073%2Fpnas.1207759109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0liwNOfq_ISdcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520conformations%252C%2520interactions%252C%2520and%2520properties%2520associated%2520with%2520drug%2520efficiency%2520and%2520clinical%2520performance%2520among%2520VEGFR%2520TK%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289%26doi%3D10.1073%2Fpnas.1207759109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0liYl5auQkEIUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Chaikuad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacconi, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsounas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/nchembio.1629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnchembio.1629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=25195011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=853-860&author=A.+Chaikuadauthor=E.+M.+Tacconiauthor=J.+Zimmerauthor=Y.+Liangauthor=N.+S.+Grayauthor=M.+Tarsounasauthor=S.+Knapp&title=A+unique+inhibitor+binding+site+in+ERK1%2F2+is+associated+with+slow+binding+kinetics&doi=10.1038%2Fnchembio.1629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span></div><div class="casAuthors">Chaikuad, Apirat; M C Tacconi, Eliana; Zimmer, Jutta; Liang, Yanke; Gray, Nathanael S.; Tarsounas, Madalena; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">853-860</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs.  Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor.  Here we report the structural mechanism for its remarkable selectivity.  In ERK1/2, SCH772984 induces a so-far-unknown binding pocket that accommodates the piperazine-phenyl-pyrimidine decoration.  This new binding pocket was created by an inactive conformation of the phosphate-binding loop and an outward tilt of helix αC.  In contrast, structure detn. of SCH772984 with the off-target haspin and JNK1 revealed two canonical but distinct type I binding modes.  Notably, the new binding mode with ERK1/2 was assocd. with slow binding kinetics in vitro as well as in cell-based assay systems.  The described binding mode of SCH772984 with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdNjmmeHD_-LVg90H21EOLACvtfcHk0liYl5auQkEIUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN&md5=b54251bd7486f0df266d8423ae9c627d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1629%26sid%3Dliteratum%253Aachs%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DTacconi%26aufirst%3DE.%2BM.%26aulast%3DZimmer%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTarsounas%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DA%2520unique%2520inhibitor%2520binding%2520site%2520in%2520ERK1%252F2%2520is%2520associated%2520with%2520slow%2520binding%2520kinetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D853%26epage%3D860%26doi%3D10.1038%2Fnchembio.1629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallwood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koretke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calamari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span> </span><span class="NLM_article-title">Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1791</span><span class="NLM_x">–</span> <span class="NLM_lpage">1797</span><span class="refDoi"> DOI: 10.1110/ps.036590.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1110%2Fps.036590.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=18662907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cit7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1791-1797&author=B.+Zhaoauthor=A.+Smallwoodauthor=J.+Yangauthor=K.+Koretkeauthor=K.+Nurseauthor=A.+Calamariauthor=R.+B.+Kirkpatrickauthor=Z.+Lai&title=Modulation+of+kinase-inhibitor+interactions+by+auxiliary+protein+binding%3A+crystallography+studies+on+Aurora+A+interactions+with+VX-680+and+with+TPX2&doi=10.1110%2Fps.036590.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2</span></div><div class="casAuthors">Zhao, Baoguang; Smallwood, Angela; Yang, Jingsong; Koretke, Kristin; Nurse, Kelvin; Calamari, Amy; Kirkpatrick, Robert B.; Lai, Zhihong</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1791-1797</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">VX-680, also known as MK-0457, is an ATP-competitive small mol. inhibitor of the Aurora kinases that has entered phase II clin. trials for the treatment of cancer.  We have solved the cocrystal structure of AurA/TPX2/VX-680 at 2.3 Å resoln.  In the crystal structure, VX-680 binds to the active conformation of AurA.  The glycine-rich loop in AurA adopts a unique bent conformation, forming a π-π interaction with the Ph group of VX-680.  In contrast, in the published AurA/VX-680 structure, VX-680 binds to AurA in the inactive conformation, interacting with a hydrophobic pocket only present in the inactive conformation.  These data suggest that TPX2, a protein cofactor, can alter the binding mode of VX-680 with AurA.  More generally, the presence of physiol. relevant cofactor proteins can alter the kinetics, binding interactions, and inhibition of enzymes, and studies with these multiprotein complexes may be beneficial to the discovery and optimization of enzyme inhibitors as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7jnb6hGH-SbVg90H21EOLACvtfcHk0liYl5auQkEIUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cit7rM&md5=622cf5907d6af38a1bc53481fd0b35d4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1110%2Fps.036590.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.036590.108%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKoretke%26aufirst%3DK.%26aulast%3DNurse%26aufirst%3DK.%26aulast%3DCalamari%26aufirst%3DA.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DLai%26aufirst%3DZ.%26atitle%3DModulation%2520of%2520kinase-inhibitor%2520interactions%2520by%2520auxiliary%2520protein%2520binding%253A%2520crystallography%2520studies%2520on%2520Aurora%2520A%2520interactions%2520with%2520VX-680%2520and%2520with%2520TPX2%26jtitle%3DProtein%2520Sci.%26date%3D2008%26volume%3D17%26spage%3D1791%26epage%3D1797%26doi%3D10.1110%2Fps.036590.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lhIvBhwiyf_NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peet, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">The kinetics of binding to p38MAP kinase by analogues of BIRB 796</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3101</span><span class="NLM_x">–</span> <span class="NLM_lpage">3104</span><span class="refDoi"> DOI: 10.1016/S0960-894X(03)00656-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS0960-894X%2803%2900656-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=12941343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1Gmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3101-3104&author=J.+Reganauthor=C.+A.+Pargellisauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=E.+R.+Hickeyauthor=G.+W.+Peetauthor=A.+Protoauthor=A.+Swinamerauthor=N.+Moss&title=The+kinetics+of+binding+to+p38MAP+kinase+by+analogues+of+BIRB+796&doi=10.1016%2FS0960-894X%2803%2900656-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of binding to p38 MAP kinase of analogues of BIRB 796</span></div><div class="casAuthors">Regan, John; Pargellis, Christopher A.; Cirillo, Pier F.; Gilmore, Thomas; Hickey, Eugene R.; Peet, Gregory W.; Proto, Alfred; Swinamer, Alan; Moss, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3101-3104</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">BIRB 796, a member of the N-pyrazole-N'-naphthyl urea class of p38 MAPK inhibitors, binds to the kinase with both slow assocn. and dissocn. rates.  Prior to binding, the kinase undergoes a reorganization of the activation loop exposing a crit. binding domain.  We demonstrate that, independent of the loop movement, assocn. rates are governed by low energy conformations of the inhibitor and polar functionality on the tolyl ring.  As anticipated, the dissocn. rates of the inhibitors from the kinase are slowed by lipophilic and hydrogen bond interactions.  The value of structure-kinetic relationships (SKR) in drug design is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr1jPKElIlvrVg90H21EOLACvtfcHk0lhIvBhwiyf_NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1Gmt7s%253D&md5=1ca2cb661cf037790ec1b0b43a105cf3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900656-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900656-5%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DPeet%26aufirst%3DG.%2BW.%26aulast%3DProto%26aufirst%3DA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DThe%2520kinetics%2520of%2520binding%2520to%2520p38MAP%2520kinase%2520by%2520analogues%2520of%2520BIRB%2520796%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D3101%26epage%3D3104%26doi%3D10.1016%2FS0960-894X%2803%2900656-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lhIvBhwiyf_NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkoczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lhIvBhwiyf_NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgDMz28Rs6a-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Shultz, M. D.</span><span> </span><span class="NLM_article-title">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5980</span><span class="NLM_x">–</span> <span class="NLM_lpage">5991</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmcl.2013.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24018190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+expectations+in+molecular+optimizations%3A+Strengths+and+limitations+of+commonly+used+composite+parameters&doi=10.1016%2Fj.bmcl.2013.08.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5980-5991</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the past 15 years there have been extensive efforts to understand and reduce the high attrition rates of drug candidates with an increased focus on physicochem. properties.  The fruits of this labor have been the generation of numerous efficiency indexes, metric-based rules and visualization tools to help guide medicinal chemists in the design of new compds. with more favorable properties.  This deluge of information may have had the unintended consequence of further obfuscating mol. optimizations by the inability of these scoring functions, rules and guides to reach a consensus on when a particular transformation is identified as beneficial.  In this manuscript, several composite parameters, or efficiency indexes, are examd. utilizing theor. and exptl. matched mol. pair analyses in order to understand the basis for how each will perform under varying scenarios of mol. optimizations.  In contrast to empirically derived composite parameters based on heavy atom count, lipophilic efficiency (LipE) sets consistent expectations regardless of mol. wt. or relative potency and can be used to generate consistent expectations for any matched mol. pair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJeTISXSJyLbVg90H21EOLACvtfcHk0lgDMz28Rs6a-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI&md5=3b766e26254f482b75b8973888c13aec</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520expectations%2520in%2520molecular%2520optimizations%253A%2520Strengths%2520and%2520limitations%2520of%2520commonly%2520used%2520composite%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991%26doi%3D10.1016%2Fj.bmcl.2013.08.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wen-Hsing Lin, Su-Ying Wu, Teng-Kuang Yeh, Chiung-Tong Chen, Jen-Shin Song, Hui-Yi Shiao, Ching-Chuan Kuo, Tsu Hsu, Cheng-Tai Lu, Pei-Chen Wang, Tsung-Sheng Wu, Yi-Hui Peng, Hui-You Lin, Ching-Ping Chen, Ya-Ling Weng, Fang-Chun Kung, Mine-Hsine Wu, Yu-Chieh Su, Kuo-Wei Huang, Ling-Hui Chou, Ching-Cheng Hsueh, Kuei-Jung Yen, Po-Chu Kuo, Chen-Lung Huang, Li-Tzong Chen, Chuan Shih, Hui-Jen Tsai, <span class="NLM_string-name hlFld-ContribAuthor">Weir-Torn Jiaang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 11135-11150. <a href="https://doi.org/10.1021/acs.jmedchem.9b01229" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01229%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Ba%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BGastrointestinal%252BStromal%252BTumors%252Band%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DLin%26aufirst%3DWen-Hsing%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30072019%26date%3D06122019%26date%3D13112019%26volume%3D62%26issue%3D24%26spage%3D11135%26epage%3D11150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Huidong  Yu</span>, <span class="hlFld-ContribAuthor ">Qinglan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Hu  Chen</span>, <span class="hlFld-ContribAuthor ">Jiean  Chen</span>, <span class="hlFld-ContribAuthor ">Qi  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Yu  Kang</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Wenfang  Zhou</span>, <span class="hlFld-ContribAuthor ">Sheng  Tian</span>, <span class="hlFld-ContribAuthor ">Sunliang  Cui</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Yong  Huang</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2017,</strong> <em>3 </em>
                                    (11)
                                     , 1208-1220. <a href="https://doi.org/10.1021/acscentsci.7b00419" title="DOI URL">https://doi.org/10.1021/acscentsci.7b00419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.7b00419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.7b00419%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DCombating%252BDrug-Resistant%252BMutants%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bwith%252BPotent%252Band%252BSelective%252BType-I1%25252F2%252BInhibitors%252Bby%252BStabilizing%252BUnique%252BDFG-Shifted%252BLoop%252BConformation%26aulast%3DPan%26aufirst%3DPeichen%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09092017%26date%3D03112017%26date%3D22112017%26volume%3D3%26issue%3D11%26spage%3D1208%26epage%3D1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marwa F.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Eman Y.  Santali</span>, <span class="hlFld-ContribAuthor ">Radwan  El-Haggar</span>. </span><span class="cited-content_cbyCitation_article-title">Novel piperazine–chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 307-318. <a href="https://doi.org/10.1080/14756366.2020.1861606" title="DOI URL">https://doi.org/10.1080/14756366.2020.1861606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1861606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1861606%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bpiperazine%2525E2%252580%252593chalcone%252Bhybrids%252Band%252Brelated%252Bpyrazoline%252Banalogues%252Btargeting%252BVEGFR-2%252Bkinase%25253B%252Bdesign%25252C%252Bsynthesis%25252C%252Bmolecular%252Bdocking%252Bstudies%25252C%252Band%252Banticancer%252Bevaluation%26aulast%3DAhmed%26aufirst%3DMarwa%2BF.%26date%3D2021%26date%3D2020%26volume%3D36%26issue%3D1%26spage%3D307%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Haibo  Sun</span>, <span class="hlFld-ContribAuthor ">Laixue  Pang</span>, <span class="hlFld-ContribAuthor ">Baohua  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2020,</strong> <em>34 </em>
                                    (12)
                                     , 1289-1305. <a href="https://doi.org/10.1007/s10822-020-00355-5" title="DOI URL">https://doi.org/10.1007/s10822-020-00355-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-020-00355-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-020-00355-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DMutation-mediated%252Binfluences%252Bon%252Bbinding%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bto%252Bcrizotinib%252Bdecoded%252Bby%252Bmultiple%252Breplica%252BGaussian%252Baccelerated%252Bmolecular%252Bdynamics%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D12%26spage%3D1289%26epage%3D1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katarzyna  Iżykowska</span>, <span class="hlFld-ContribAuthor ">Karolina  Rassek</span>, <span class="hlFld-ContribAuthor ">Dorota  Korsak</span>, <span class="hlFld-ContribAuthor ">Grzegorz K.  Przybylski</span>. </span><span class="cited-content_cbyCitation_article-title">Novel targeted therapies of T cell lymphomas. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-01006-w" title="DOI URL">https://doi.org/10.1186/s13045-020-01006-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-01006-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-01006-w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DNovel%252Btargeted%252Btherapies%252Bof%252BT%252Bcell%252Blymphomas%26aulast%3DI%25C5%25BCykowska%26aufirst%3DKatarzyna%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima Ezzahra  Bennani</span>, <span class="hlFld-ContribAuthor ">Latifa  Doudach</span>, <span class="hlFld-ContribAuthor ">Yahia  Cherrah</span>, <span class="hlFld-ContribAuthor ">Youssef  Ramli</span>, <span class="hlFld-ContribAuthor ">Khalid  Karrouchi</span>, <span class="hlFld-ContribAuthor ">M'hammed  Ansar</span>, <span class="hlFld-ContribAuthor ">My El Abbes  Faouzi</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>97 </em>, 103470. <a href="https://doi.org/10.1016/j.bioorg.2019.103470" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103470%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DOverview%252Bof%252Brecent%252Bdevelopments%252Bof%252Bpyrazole%252Bderivatives%252Bas%252Ban%252Banticancer%252Bagent%252Bin%252Bdifferent%252Bcell%252Bline%26aulast%3DBennani%26aufirst%3DFatima%2BEzzahra%26date%3D2020%26volume%3D97%26spage%3D103470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Sicong  Liu</span>, <span class="hlFld-ContribAuthor ">Shiliang  Yin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Dajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103456. <a href="https://doi.org/10.1016/j.bioorg.2019.103456" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103456%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-arylaminopyrimidine%252Bderivatives%252Bbearing%252B1%25252C3%25252C8-triazaspiro%25255B4%25252C5%25255Ddecan-4-one%252Bor%252Bpiperidine-3-carboxamide%252Bmoiety%252Bas%252Bnovel%252BType-I1%25252F2%252BALK%252Binhibitors%26aulast%3DMiao%26aufirst%3DXiuqi%26date%3D2020%26volume%3D94%26spage%3D103456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Ridong  Li</span>, <span class="hlFld-ContribAuthor ">Xianling  Ning</span>, <span class="hlFld-ContribAuthor ">Xuyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan  Jin</span>, <span class="hlFld-ContribAuthor ">Yuxin  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 141-153. <a href="https://doi.org/10.1016/j.ejmech.2019.05.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Banti-tumor%252Befficacy%252Bof%252Bnovel%252B2%25252C%252B4-diarylaminopyrimidine%252Bderivatives%252Bbearing%252BN-%2525283-pyridinylmethyl%252529%252Burea%252Bmoiety%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%26aulast%3DChen%26aufirst%3DHong%26date%3D2019%26volume%3D178%26spage%3D141%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nancy  Abdelgawad</span>, <span class="hlFld-ContribAuthor ">Mahmoud F.  Ismail</span>, <span class="hlFld-ContribAuthor ">Mohamed H.  Hekal</span>, <span class="hlFld-ContribAuthor ">Magda I.  Marzouk</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of Some Novel Heterocycles Bearing Pyrazole Moiety as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2019,</strong> <em>56 </em>
                                    (6)
                                     , 1771-1779. <a href="https://doi.org/10.1002/jhet.3544" title="DOI URL">https://doi.org/10.1002/jhet.3544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3544%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252BSome%252BNovel%252BHeterocycles%252BBearing%252BPyrazole%252BMoiety%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DAbdelgawad%26aufirst%3DNancy%26date%3D2019%26date%3D2019%26volume%3D56%26issue%3D6%26spage%3D1771%26epage%3D1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nattawut  Sawengngen</span>, <span class="hlFld-ContribAuthor ">Petrakis N.  Chalikidi</span>, <span class="hlFld-ContribAuthor ">Sara  Araby</span>, <span class="hlFld-ContribAuthor ">Frank  Hampel</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>, <span class="hlFld-ContribAuthor ">Olga V.  Serdyuk</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of pyrazolylvinyl ketones from furan derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (19)
                                     , 4850-4855. <a href="https://doi.org/10.1039/C9OB00701F" title="DOI URL">https://doi.org/10.1039/C9OB00701F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB00701F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB00701F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bpyrazolylvinyl%252Bketones%252Bfrom%252Bfuran%252Bderivatives%26aulast%3DSawengngen%26aufirst%3DNattawut%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D19%26spage%3D4850%26epage%3D4855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Hua  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Mei  Wu</span>, <span class="hlFld-ContribAuthor ">Sai-Nan  Deng</span>, <span class="hlFld-ContribAuthor ">Rui-Xia  Chai</span>, <span class="hlFld-ContribAuthor ">Muriira Cyrus  Mwenda</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Peng</span>, <span class="hlFld-ContribAuthor ">Dong  Cai</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2,4-disubstituted thiazole amide derivatives as anticancer agent. </span><span class="cited-content_cbyCitation_journal-name">Chemical Papers</span><span> <strong>2019,</strong> <em>73 </em>
                                    (2)
                                     , 355-364. <a href="https://doi.org/10.1007/s11696-018-0587-3" title="DOI URL">https://doi.org/10.1007/s11696-018-0587-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11696-018-0587-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11696-018-0587-3%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Papers%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2%25252C4-disubstituted%252Bthiazole%252Bamide%252Bderivatives%252Bas%252Banticancer%252Bagent%26aulast%3DZhang%26aufirst%3DZhi-Hua%26date%3D2019%26date%3D2018%26volume%3D73%26issue%3D2%26spage%3D355%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aladdin M.  Srour</span>, <span class="hlFld-ContribAuthor ">Hoda H.  Fahmy</span>, <span class="hlFld-ContribAuthor ">Mai A.  Khater</span>, <span class="hlFld-ContribAuthor ">May A.  El-Manawaty</span>, <span class="hlFld-ContribAuthor ">ElSayed M.  Shalaby</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization, and cytotoxic activity of some new 1,3,4-trisubstituted pyrazoles against diverse tumor cell lines. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2018,</strong> <em>149 </em>
                                    (6)
                                     , 1137-1147. <a href="https://doi.org/10.1007/s00706-018-2153-7" title="DOI URL">https://doi.org/10.1007/s00706-018-2153-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-018-2153-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-018-2153-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DSynthesis%25252C%252Bcharacterization%25252C%252Band%252Bcytotoxic%252Bactivity%252Bof%252Bsome%252Bnew%252B1%25252C3%25252C4-trisubstituted%252Bpyrazoles%252Bagainst%252Bdiverse%252Btumor%252Bcell%252Blines%26aulast%3DSrour%26aufirst%3DAladdin%2BM.%26date%3D2018%26date%3D2018%26volume%3D149%26issue%3D6%26spage%3D1137%26epage%3D1147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>, <span class="hlFld-ContribAuthor ">Shan  Chang</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2018,</strong> <em>20 </em>
                                    (7)
                                     , 4851-4863. <a href="https://doi.org/10.1039/C7CP08241J" title="DOI URL">https://doi.org/10.1039/C7CP08241J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CP08241J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CP08241J%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DImportance%252Bof%252Bprotein%252Bflexibility%252Bin%252Bmolecular%252Brecognition%25253A%252Ba%252Bcase%252Bstudy%252Bon%252BType-I1%25252F2%252Binhibitors%252Bof%252BALK%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2018%26date%3D2018%26volume%3D20%26issue%3D7%26spage%3D4851%26epage%3D4863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raquib  Alam</span>, <span class="hlFld-ContribAuthor ">Md. Aftab  Alam</span>, <span class="hlFld-ContribAuthor ">Amulya K.  Panda</span>, <span class="hlFld-ContribAuthor ">Rahisuddin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Cytotoxicity Evaluation of 3‐(5‐(3‐(aryl)‐1‐phenyl‐1H‐pyrazol‐4‐yl)‐1‐phenyl‐4,5‐dihydro‐1H‐pyrazol‐3‐yl)pyridine and 5‐(3‐(aryl)‐1‐phenyl‐1H‐pyrazol‐4‐yl)‐3‐(pyridin‐3‐yl)‐4,5‐dihydropyrazole‐1‐carbaldehyde Derivatives as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2017,</strong> <em>54 </em>
                                    (3)
                                     , 1812-1821. <a href="https://doi.org/10.1002/jhet.2768" title="DOI URL">https://doi.org/10.1002/jhet.2768</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.2768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.2768%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BCytotoxicity%252BEvaluation%252Bof%252B3%2525E2%252580%252590%2525285%2525E2%252580%252590%2525283%2525E2%252580%252590%252528aryl%252529%2525E2%252580%2525901%2525E2%252580%252590phenyl%2525E2%252580%2525901H%2525E2%252580%252590pyrazol%2525E2%252580%2525904%2525E2%252580%252590yl%252529%2525E2%252580%2525901%2525E2%252580%252590phenyl%2525E2%252580%2525904%25252C5%2525E2%252580%252590dihydro%2525E2%252580%2525901H%2525E2%252580%252590pyrazol%2525E2%252580%2525903%2525E2%252580%252590yl%252529pyridine%252Band%252B5%2525E2%252580%252590%2525283%2525E2%252580%252590%252528aryl%252529%2525E2%252580%2525901%2525E2%252580%252590phenyl%2525E2%252580%2525901H%2525E2%252580%252590pyrazol%2525E2%252580%2525904%2525E2%252580%252590yl%252529%2525E2%252580%2525903%2525E2%252580%252590%252528pyridin%2525E2%252580%2525903%2525E2%252580%252590yl%252529%2525E2%252580%2525904%25252C5%2525E2%252580%252590dihydropyrazole%2525E2%252580%2525901%2525E2%252580%252590carbaldehyde%252BDerivatives%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DAlam%26aufirst%3DRaquib%26date%3D2017%26date%3D2016%26volume%3D54%26issue%3D3%26spage%3D1812%26epage%3D1821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Jinan  Wang</span>, <span class="hlFld-ContribAuthor ">Weiliang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2017,</strong> <em>19 </em>
                                    (44)
                                     , 30239-30248. <a href="https://doi.org/10.1039/C7CP05418A" title="DOI URL">https://doi.org/10.1039/C7CP05418A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CP05418A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CP05418A%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DMutation%252BL1196M-induced%252Bconformational%252Bchanges%252Band%252Bthe%252Bdrug%252Bresistant%252Bmechanism%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bstudied%252Bby%252Bfree%252Benergy%252Bperturbation%252Band%252Bumbrella%252Bsampling%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D44%26spage%3D30239%26epage%3D30248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raquib  Alam</span>, <span class="hlFld-ContribAuthor ">Divya  Wahi</span>, <span class="hlFld-ContribAuthor ">Raja  Singh</span>, <span class="hlFld-ContribAuthor ">Devapriya  Sinha</span>, <span class="hlFld-ContribAuthor ">Vibha  Tandon</span>, <span class="hlFld-ContribAuthor ">Abhinav  Grover</span>, <span class="hlFld-ContribAuthor ">Rahisuddin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2016,</strong> <em>69 </em>, 77-90. <a href="https://doi.org/10.1016/j.bioorg.2016.10.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2016.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2016.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2016.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bcytotoxicity%25252C%252BHuTopoII%2525CE%2525B1%252Binhibitory%252Bactivity%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bpyrazole%252Bderivatives%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DAlam%26aufirst%3DRaquib%26date%3D2016%26volume%3D69%26spage%3D77%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) pyridine, rt, (ii) H<sub>2</sub>, Pd/C, MeOH/HCl (aq); (b) pyridine, phenyl isocyanate or (5-alkylisoxazol-3-yl)carbamic acid 4-nitrophenyl ester, rt.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Pharmacophore of <b>5a</b>, the type II ALK inhibitor. <b>5a</b> was divided into five different portions, including the water-exposed headgroup (yellow), hinge binding group (cyan), aromatic linker (green), hydrogen bonding motif (purple), and tail group (purple). (B) Crystal structure of ALK in complex with <b>5a</b> (yellow stick). Hydrogen bond and charge–charge interaction are shown with red and green dashed lines, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Superposition of the crystal structure of ALK/<b>5a</b> with ALK/<b>5d</b> gave a rmsd of 0.354 Å for 284 C<sub>α</sub> atom. Both the <i>tert</i>-butyl group of <b>5a</b> (yellow) and the isopropyl group of <b>5d</b> (cyan) extended into the hydrophobic pocket. As compared with the structure of ALK/<b>5a</b>, the isopropyl group of <b>5d</b> loses the interactions with Phe1174, Ile1179, and Phe1245 (marked in green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Spatial arrangement of the αC-helix (cyan), α-AL helix (purple), and JM domain (green) in apo ALK structure. (B) Spatial arrangement of the αC-helix, α-AL, and JM domain in ALK/<b>5a</b> structure. (C) Comparison of the structures of apo ALK (pale purple) and ALK/<b>5a</b> (pale pink). Binding of <b>5a</b> unfolds the α-AL to a nonstructural loop and moves α-AL away from the αC-helix, which consequently shifts the αC-helix away from C-lobe to an open state. In addition, the JM domain concurrently transforms from the antiparallel β-turn conformation to the helix conformation. Red arrow indicates that αC-helix shifts outward to an open state upon the binding of <b>5a</b>. (D) A 60° rotated view of (C). Binding of <b>5a</b> induces the dramatic conformation change of JM domain. Reorientation of αC-helix to an open state upon the binding of <b>5a</b> would clash with JM domain (explosion drawing represents the vdw overlapping and steric clashing).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Catalytic spine (C-spine, pale blue) and regulatory spine (R-spine, pale green) coordinated the internal architecture of ALK. Both hydrophobic spines reached from the N-lobe to the C-lobe of the kinases and anchored to the F-helix. (B) Incorporation of <b>5a</b> completed the C-spine and R-spine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Superposition of the crystal structure of ALK/<b>5a</b> with ALK/<b>4</b>. Binding of <b>5a</b> induces the conformational changes of αC-helix, A-loop, and JM domain. In the absence of the substituted-urea tail moiety, no ligand-induced conformational changes were observed in ALK/<b>4</b> structure. (B) Interaction network of <b>4</b> with ALK. (C) The P-loop of ALK/<b>4</b> adopts a distinct conformation among the different ALK structures. Bending of the P-loop oriented Phe1127 into the ATP binding site and directly stacked to the tolyl group of <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/medium/jm-2016-00106d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Schematic representation of type I inhibitor crizotinib and type II inhibitors, <b>6</b> and <b>5a</b>. (B, C) Superimposition of the ALK/<b>5a</b> structure with ALK/crizotinib structure. (D, E) Superimposition of the ALK/<b>5a</b> structure with ALK/<b>6</b>. Hydrogen bonds between ALK/<b>5a</b> and ALK/crizotinib (or ALK/<b>6</b>) are shown with red and green dashed lines, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00106&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36168" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0lgN_lAxSuTXvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hallberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, R. H.</span><span> </span><span class="NLM_article-title">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/nrc3580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnrc3580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24060861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=685-700&author=B.+Hallbergauthor=R.+H.+Palmer&title=Mechanistic+insight+into+ALK+receptor+tyrosine+kinase+in+human+cancer+biology&doi=10.1038%2Fnrc3580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</span></div><div class="casAuthors">Hallberg, Bengt; Palmer, Ruth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">685-700</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC).  The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK.  In this review, we discuss our current understanding of ALK function in human cancer and the implications for tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADI-N0ZBEr7Vg90H21EOLACvtfcHk0lgN_lAxSuTXvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jtrbP&md5=fab66b12114ca01348df4ca08d3b3e4e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3580%26sid%3Dliteratum%253Aachs%26aulast%3DHallberg%26aufirst%3DB.%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26atitle%3DMechanistic%2520insight%2520into%2520ALK%2520receptor%2520tyrosine%2520kinase%2520in%2520human%2520cancer%2520biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D685%26epage%3D700%26doi%3D10.1038%2Fnrc3580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1016/j.phrs.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.phrs.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23201355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=68-94&author=R.+Roskoski&title=Anaplastic+lymphoma+kinase+%28ALK%29%3A+structure%2C+oncogenic+activation%2C+and+pharmacological+inhibition&doi=10.1016%2Fj.phrs.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-94</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.  ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.  Physiol. ALK participates in embryonic nervous system development, but its expression decreases after birth.  ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.  Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.  The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.  The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.  Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.  Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.  The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.  Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-pos. non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.  The emergence of crizotinib drug resistance with a median occurrence at approx. 10 mo after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders.  About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.  It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-pos. non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-sp0x0gqkrVg90H21EOLACvtfcHk0lgN_lAxSuTXvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVygtg%253D%253D&md5=c48d1a4b88a68d395b7acdf403f1875d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520structure%252C%2520oncogenic%2520activation%252C%2520and%2520pharmacological%2520inhibition%26jtitle%3DPharmacol.%2520Res.%26date%3D2013%26volume%3D68%26spage%3D68%26epage%3D94%26doi%3D10.1016%2Fj.phrs.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">New strategies for treatment of ALK-rearranged non-small cell lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7213</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F1078-0432.CCR-11-1404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22010214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7213-7218&author=T.+Sasakiauthor=P.+A.+Janne&title=New+strategies+for+treatment+of+ALK-rearranged+non-small+cell+lung+cancers&doi=10.1158%2F1078-0432.CCR-11-1404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers</span></div><div class="casAuthors">Sasaki, Takaaki; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7213-7218</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The identification of oncogenic alterations in subsets of patients with non-small cell lung cancer (NSCLC) is transforming clin. care.  Genomic rearrangements in anaplastic lymphoma kinase (ALK) are detected in 3% to 7% of patients with NSCLC.  The ALK tyrosine kinase inhibitor crizotinib has demonstrated clin. efficacy in ALK-rearranged NSCLC patients and was recently approved by the U.S.  Food and Drug Administration.  Crizotinib is currently under addnl. phase III clin. development as both initial and second-line therapy for advanced ALK-rearranged NSCLC.  However, new challenges in the diagnosis and treatment of this subset of NSCLC have emerged, including the need to det. the most effective means of diagnosing ALK-rearranged NSCLC and the emergence of acquired drug resistance to crizotinib.  In this review, we discuss current strategies for treatment and diagnosis, as well as the current knowledge about mechanisms of acquired resistance to crizotinib.  Finally, we discuss the strategies that are underway to clin. overcome acquired drug resistance.  Clin Cancer Res; 17(23); 7213-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocg76jJ18-jrVg90H21EOLACvtfcHk0lhKzdQJ9uLk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmtrzP&md5=adc9f7969982dbcd1ad9b8c2c639ef0e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1404%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNew%2520strategies%2520for%2520treatment%2520of%2520ALK-rearranged%2520non-small%2520cell%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7213%26epage%3D7218%26doi%3D10.1158%2F1078-0432.CCR-11-1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lhKzdQJ9uLk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lhKzdQJ9uLk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span><span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.+Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulf+onyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0liOcYD1D0hxyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.%2BQ.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulf%2520onyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konagai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fushiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakagami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+selective+anaplastic+lymphoma+receptor+tyrosine+kinase+inhibitor+ASP3026+induces+tumor+regression+and+prolongs+survival+in+non-small+cell+lung+cancer+model+mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0liOcYD1D0hxyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520selective%2520anaplastic%2520lymphoma%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ASP3026%2520induces%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520non-small%2520cell%2520lung%2520cancer%2520model%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giudici, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piazza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-14-0157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F1541-7786.MCR-14-0157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=25421750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlChtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=775-783&author=M.+Cecconauthor=L.+Mologniauthor=G.+Giudiciauthor=R.+Piazzaauthor=A.+Pirolaauthor=D.+Fontanaauthor=C.+Gambacorti-Passerini&title=Treatment+efficacy+and+resistance+mechanisms+using+the+second-generation+ALK+inhibitor+AP26113+in+human+NPM-ALK-positive+anaplastic+large+cell+lymphoma&doi=10.1158%2F1541-7786.MCR-14-0157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma</span></div><div class="casAuthors">Ceccon, M.; Mologni, L.; Giudici, G.; Piazza, R.; Pirola, A.; Fontana, D.; Gambacorti-Passerini, C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">775-783</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ALK is a tyrosine kinase receptor involved in a broad range of solid and hematol. tumors.  Among 70% to 80% of ALK+ anaplastic large cell lymphomas (ALCL) are caused by the aberrant oncogenic fusion protein NPM-ALK.  Crizotinib was the first clin. relevant ALK inhibitor, now approved for the treatment of late-stage and metastatic cases of lung cancer.  However, patients frequently develop drug resistance to Crizotinib, mainly due to the appearance of point mutations located in the ALK kinase domain.  Fortunately, other inhibitors are available and in clin. trial, suggesting the potential for second-line therapies to overcome Crizotinib resistance.  This study focuses on the ongoing phase I/II trial small-mol. tyrosine kinase inhibitor (TKI) AP26113, by Ariad Pharmaceuticals, which targets both ALK and EGFR.  Two NPM-ALK+ human cell lines, KARPAS-299 and SUP-M2, were grown in the presence of increasing concns. of AP26113, and eight lines were selected that demonstrated resistance.  All lines show IC50 values higher (130 to 1,000-fold) than the parental line.  Mechanistically, KARPAS-299 populations resistant to AP26113 show NPM-ALK overexpression, whereas SUP-M2-resistant cells harbor several point mutations spanning the entire ALK kinase domain.  In particular, amino acid substitutions: L1196M, S1206C, the double F1174V+L1198F and L1122V+L1196M mutations were identified.  The knowledge of the possible appearance of new clin. relevant mechanisms of drug resistance is a useful tool for the management of new TKI-resistant cases.  Implications: This work defines reliable ALCL model systems of AP26113 resistance and provides a valuable tool in the management of all cases of relapse upon NPM-ALK-targeted therapy.  Mol Cancer Res; 13(4); 775-83. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoejoukJP2mhbVg90H21EOLACvtfcHk0ljsAvAn5ZU3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlChtrk%253D&md5=3922eb8e16f1748fd4b1e5f932df4ae4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-14-0157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-14-0157%26sid%3Dliteratum%253Aachs%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DGiudici%26aufirst%3DG.%26aulast%3DPiazza%26aufirst%3DR.%26aulast%3DPirola%26aufirst%3DA.%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DTreatment%2520efficacy%2520and%2520resistance%2520mechanisms%2520using%2520the%2520second-generation%2520ALK%2520inhibitor%2520AP26113%2520in%2520human%2520NPM-ALK-positive%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2015%26volume%3D13%26spage%3D775%26epage%3D783%26doi%3D10.1158%2F1541-7786.MCR-14-0157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0ljsAvAn5ZU3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Rothenstein, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letarte, N.</span><span> </span><span class="NLM_article-title">Managing treatment-related adverse events associated with Alk inhibitors</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.3747/co.21.1740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.3747%2Fco.21.1740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24523601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A280%3ADC%252BC2cvkslynsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=19-26&author=J.+M.+Rothensteinauthor=N.+Letarte&title=Managing+treatment-related+adverse+events+associated+with+Alk+inhibitors&doi=10.3747%2Fco.21.1740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Managing treatment-related adverse events associated with Alk inhibitors</span></div><div class="casAuthors">Rothenstein J M; Letarte N</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology (Toronto, Ont.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-26</span>
        ISSN:<span class="NLM_cas:issn">1198-0052</span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) rearrangements have been identified as key oncogenic drivers in a small subset of non-small-cell lung cancers (nsclcs).  Small-molecule Alk kinase inhibitors such as crizotinib have transformed the natural history of nsclc for this subgroup of patients.  Because of the prevalence of nsclc, ALK-positive patients represent an important example of the paradigm for personalized medicine.  Although Alk inhibitors such as crizotinib are well tolerated, there is a potential for adverse events to occur.  Proactive monitoring, treatment, and education concerning those adverse events will help to optimize the therapeutic index of the drugs.  The present review summarizes the management of treatment-related adverse events that can arise with Alk inhibitors such as crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThWqYfhR02EYHWj6b1v8uTfW6udTcc2eaaOPkNWmwfX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvkslynsg%253D%253D&md5=5644f6915b4324fcf3abf119e7de6456</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3747%2Fco.21.1740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.21.1740%26sid%3Dliteratum%253Aachs%26aulast%3DRothenstein%26aufirst%3DJ.%2BM.%26aulast%3DLetarte%26aufirst%3DN.%26atitle%3DManaging%2520treatment-related%2520adverse%2520events%2520associated%2520with%2520Alk%2520inhibitors%26jtitle%3DCurr.%2520Oncol.%26date%3D2014%26volume%3D21%26spage%3D19%26epage%3D26%26doi%3D10.3747%2Fco.21.1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1019</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70344-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS1470-2045%2812%2970344-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22954507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1011-1019&author=D.+R.+Camidgeauthor=Y.+J.+Bangauthor=E.+L.+Kwakauthor=A.+J.+Iafrateauthor=M.+Varella-Garciaauthor=S.+B.+Foxauthor=G.+J.+Rielyauthor=B.+Solomonauthor=S.+H.+I.+Ouauthor=D.+W.+Kimauthor=R.+Salgiaauthor=P.+Fidiasauthor=J.+A.+Engelmanauthor=L.+Gandhiauthor=P.+A.+Janneauthor=D.+B.+Costaauthor=G.+I.+Shapiroauthor=P.+LoRussoauthor=K.+Ruffnerauthor=P.+Stephensonauthor=Y.+Y.+Tangauthor=K.+Wilnerauthor=J.+W.+Clarkauthor=A.+T.+Shaw&title=Activity+and+safety+of+crizotinib+in+patients+with+ALK-positive+non-small-cell+lung+cancer%3A+updated+results+from+a+phase+1+study&doi=10.1016%2FS1470-2045%2812%2970344-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</span></div><div class="casAuthors">Camidge, D. Ross; Bang, Yung-Jue; Kwak, Eunice L.; Iafrate, A. John; Varella-Garcia, Marileila; Fox, Stephen B.; Riely, Gregory J.; Solomon, Benjamin; Ou, Sai-Hong I.; Kim, Dong-Wan; Salgia, Ravi; Fidias, Panagiotis; Engelman, Jeffrey A.; Gandhi, Leena; Jaenne, Pasi A.; Costa, Daniel B.; Shapiro, Geoffrey I.; LoRusso, Patricia; Ruffner, Katherine; Stephenson, Patricia; Tang, Yiyun; Wilner, Keith; Clark, Jeffrey W.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1011-1019</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).  We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study.  Methods: In this phase 1 study, patients with ALK-pos. stage III or IV NSCLC received oral crizotinib 250 mg twice daily in 28-day cycles.  Endpoints included tumor responses, duration of response, time to tumor response, progression-free survival (PFS), overall survival at 6 and 12 mo, and detn. of the safety and tolerability and characterization of the plasma pharmacokinetic profile of crizotinib after oral administration.  Responses were analyzed in evaluable patients and PFS and safety were analyzed in all patients.  This study is registered with ClinicalTrials.gov, no. NCT00585195.  Findings: Between Aug 27, 2008, and June 1, 2011, 149 ALK-pos. patients were enrolled, 143 of whom were included in the response-evaluable population. 87 of 143 patients had an objective response (60·8%, 95% CI 52·3-68·9), including three complete responses and 84 partial responses.  Median time to first documented objective response was 7·9 wk (range 2·1-39·6) and median duration of response was 49·1 wk (95% CI 39·3-75·4).  The response rate seemed to be largely independent of age, sex, performance status, or line of treatment.  Median PFS was 9·7 mo (95% CI 7·7-12·8).  Median overall survival data are not yet mature, but estd. overall survival at 6 and 12 mo was 87·9% (95% CI 81·3-92·3) and 74·8% (66·4-81·5), resp. 39 patients continued to receive crizotinib for more than 2 wk after progression because of perceived ongoing clin. benefit from the drug (12 for at least 6 mo from the time of their initial investigator-defined disease progression).  Overall, 144 (97%) of 149 patients experienced treatment-related adverse events, which were mostly grade 1 or 2.  The most common adverse events were visual effects, nausea, diarrhoea, constipation, vomiting, and peripheral edema.  The most common treatment-related grade 3 or 4 adverse events were neutropenia (n=9), raised alanine aminotransferase (n=6), hypophosphatemia (n=6), and lymphopenia (n=6).  Interpretation: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-pos. NSCLC.  There seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.  Funding: Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNr3aI1rrjmbVg90H21EOLACvtfcHk0lihtdB-C4lJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsb3E&md5=bd3aec44b197ee2f4c9d49ea540a672f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970344-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970344-3%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DFox%26aufirst%3DS.%2BB.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DRuffner%26aufirst%3DK.%26aulast%3DStephenson%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DY.%2BY.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DActivity%2520and%2520safety%2520of%2520crizotinib%2520in%2520patients%2520with%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%253A%2520updated%2520results%2520from%2520a%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D1011%26epage%3D1019%26doi%3D10.1016%2FS1470-2045%2812%2970344-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, L. Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, D. S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vansteenkiste, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, Y. Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boral, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">8010</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1200%2FJCO.2012.44.5353" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=8010&author=A.+T.+Shawauthor=R.+Mehraauthor=D.+W.+Kimauthor=E.+Felipauthor=L.+Q.+M.+Chowauthor=D.+R.+Camidgeauthor=D.+S.+W.+Tanauthor=J.+F.+Vansteenkisteauthor=S.+Sharmaauthor=T.+De+Pasauthor=J.+Wolfauthor=R.+Katayamaauthor=Y.+Y.+Y.+Lauauthor=M.+Goldwasserauthor=A.+Boralauthor=J.+A.+Engelman&title=Clinical+activity+of+the+ALK+inhibitor+LDK378+in+advanced%2C+ALK-positive+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.5353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.5353%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DChow%26aufirst%3DL.%2BQ.%2BM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DVansteenkiste%26aufirst%3DJ.%2BF.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLau%26aufirst%3DY.%2BY.%2BY.%26aulast%3DGoldwasser%26aufirst%3DM.%26aulast%3DBoral%26aufirst%3DA.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DClinical%2520activity%2520of%2520the%2520ALK%2520inhibitor%2520LDK378%2520in%2520advanced%252C%2520ALK-positive%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D8010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshioka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span> </span><span class="NLM_article-title">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70142-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS1470-2045%2813%2970142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23639470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=590-598&author=T.+Setoauthor=K.+Kiuraauthor=M.+Nishioauthor=K.+Nakagawaauthor=M.+Maemondoauthor=A.+Inoueauthor=T.+Hidaauthor=N.+Yamamotoauthor=H.+Yoshiokaauthor=M.+Haradaauthor=Y.+Oheauthor=N.+Nogamiauthor=K.+Takeuchiauthor=T.+Shimadaauthor=T.+Tanakaauthor=T.+Tamura&title=CH5424802+%28RO5424802%29+for+patients+with+ALK-rearranged+advanced+non-small-cell+lung+cancer+%28AF-001JP+study%29%3A+a+single-arm%2C+open-label%2C+phase+1%E2%80%932+study&doi=10.1016%2FS1470-2045%2813%2970142-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study</span></div><div class="casAuthors">Seto, Takashi; Kiura, Katsuyuki; Nishio, Makoto; Nakagawa, Kazuhiko; Maemondo, Makoto; Inoue, Akira; Hida, Toyoaki; Yamamoto, Nobuyuki; Yoshioka, Hiroshige; Harada, Masao; Ohe, Yuichiro; Nogami, Naoyuki; Takeuchi, Kengo; Shimada, Tadashi; Tanaka, Tomohiro; Tamura, Tomohide</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">590-598</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available ALK inhibitor.  In this multicenter, single-arm, open-label, phase 1-2 study of CH5424802, we recruited ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC from 13 hospitals in Japan.  In the phase 1 portion of the study, patients received CH5424802 orally twice daily by dose escalation.  The primary endpoints of the phase 1 were dose limiting toxicity (DLT), max. tolerated dose (MTD), and pharmacokinetic parameters.  In the phase 2 portion of the study, patients received CH5424802 at the recommended dose identified in the phase 1 portion of the study orally twice a day.  The primary endpoint of the phase 2 was the proportion of patients who had an objective response.  Treatment was continued in 21-day cycles until disease progression, intolerable adverse events, or withdrawal of consent.  The anal. was done by intent to treat.  This study is registered with the Japan Pharmaceutical Information Center, no. JapicCTI-101264.  Patients were enrolled between Sept 10, 2010, and Apr. 18, 2012.  The data cutoff date was July 31, 2012.  In the phase 1 portion, 24 patients were treated at doses of 20-300 mg twice daily.  No DLTs or adverse events of grade 4 were noted up to the highest dose; thus 300 mg twice daily was the recommended phase 2 dose.  In the phase 2 portion of the study, 46 patients were treated with the recommended dose, of whom 43 achieved an objective response (93·5%, 95% CI 82·1-98·6) including two complete responses (4·3%, 0·5-14·8) and 41 partial responses (89·1%, 76·4-96·4).  Treatment-related adverse events of grade 3 were recorded in 12 (26%) of 46 patients, including two patients each experiencing decreased neutrophil count and increased blood creatine phosphokinase.  Serious adverse events occurred in five patients (11%).  No grade 4 adverse events or deaths were reported.  The study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.  CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC.  Chugai Pharmaceutical Co, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnUGKVRfsBbVg90H21EOLACvtfcHk0lh0PaHevleobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntV2gsrk%253D&md5=489043eede3a37bb8ce76c6f1dc0296d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970142-6%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26atitle%3DCH5424802%2520%2528RO5424802%2529%2520for%2520patients%2520with%2520ALK-rearranged%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528AF-001JP%2520study%2529%253A%2520a%2520single-arm%252C%2520open-label%252C%2520phase%25201%25E2%2580%25932%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D590%26epage%3D598%26doi%3D10.1016%2FS1470-2045%2813%2970142-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Blanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Type II kinase inhibitors: an opportunity in cancer for rational design</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.2174/1871520611313050008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.2174%2F1871520611313050008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23094911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=731-747&author=J.+Blancauthor=R.+Geneyauthor=C.+Menet&title=Type+II+kinase+inhibitors%3A+an+opportunity+in+cancer+for+rational+design&doi=10.2174%2F1871520611313050008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Type II kinase inhibitors: an opportunity in cancer for rational design</span></div><div class="casAuthors">Blanc, Javier; Geney, Raphael; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  With the advent of the Type II kinase inhibitor imatinib (Gleevec) for treatment against cancer, rational design of tailored mols. has brought a revolution in medicinal chem. for treating tumors caused by kinase malfunctioning.  Among different types of kinase inhibitors, the design of Type II inhibitors has been rationalized for maximizing the benefits and reducing drawbacks.  Here we highlight the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of mols.  Furthermore, we present the strategies for designing druggable mols. that either selectively inhibit target kinases or overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7md6eYN1yg7Vg90H21EOLACvtfcHk0lh0PaHevleobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslyku78%253D&md5=30e72045115f723f2b868381898c2218</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1871520611313050008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611313050008%26sid%3Dliteratum%253Aachs%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DType%2520II%2520kinase%2520inhibitors%253A%2520an%2520opportunity%2520in%2520cancer%2520for%2520rational%2520design%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D731%26epage%3D747%26doi%3D10.2174%2F1871520611313050008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lh0PaHevleobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhAUnWYMhg87Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span><span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lhAUnWYMhg87Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staehle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, C. C.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and pharmacodynamics of single doses of an oral p38 MAP kinase inhibitor (BIRB 796 BS) in healthy human males - a placebo-controlled, randomised study, double blinded at each dose level</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">S67</span><span class="NLM_x">–</span> <span class="NLM_lpage">S67</span><span class="refDoi"> DOI: 10.1016/S0091-6749(02)81294-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS0091-6749%2802%2981294-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=S67-S67&author=A.+Guptaauthor=C.+L.+Yongauthor=J.+B.+Madwedauthor=H.+Staehleauthor=C.+C.+Wood&title=Safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+single+doses+of+an+oral+p38+MAP+kinase+inhibitor+%28BIRB+796+BS%29+in+healthy+human+males+-+a+placebo-controlled%2C+randomised+study%2C+double+blinded+at+each+dose+level&doi=10.1016%2FS0091-6749%2802%2981294-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0091-6749%2802%2981294-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-6749%252802%252981294-5%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DMadwed%26aufirst%3DJ.%2BB.%26aulast%3DStaehle%26aufirst%3DH.%26aulast%3DWood%26aufirst%3DC.%2BC.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520single%2520doses%2520of%2520an%2520oral%2520p38%2520MAP%2520kinase%2520inhibitor%2520%2528BIRB%2520796%2520BS%2529%2520in%2520healthy%2520human%2520males%2520-%2520a%2520placebo-controlled%252C%2520randomised%2520study%252C%2520double%2520blinded%2520at%2520each%2520dose%2520level%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D109%26spage%3DS67%26epage%3DS67%26doi%3D10.1016%2FS0091-6749%2802%2981294-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Cohen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobburu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">U, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staten, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=12006504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=935-942&author=M.+H.+Cohenauthor=G.+Williamsauthor=J.+R.+Johnsonauthor=J.+Duanauthor=J.+Gobburuauthor=A.+Rahmanauthor=K.+Bensonauthor=J.+Leightonauthor=S.+K.+Kimauthor=R.+Woodauthor=M.+Rothmannauthor=G.+Chenauthor=K.+M.+Uauthor=A.+M.+Statenauthor=R.+Pazdur&title=Approval+summary+for+imatinib+mesylate+capsules+in+the+treatment+of+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant; Johnson, John R.; Duan, John; Gobburu, Jogarao; Rahman, Atiqur; Benson, Kimberly; Leighton, John; Kim, Sung K.; Wood, Rebecca; Rothmann, Mark; Chen, Gang; Maung U., Khin; Staten, Ann M.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-942</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis.  Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines.  In this report, we describe the preclin. profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.  Chem. manufg. and controls, animal toxicol., and biopharmaceutical data are described.  Results of Phase I and Phase II clin. studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN-α (CML-CP) are summarized.  The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.  Toxicol. studies in the rat, dog, and monkey show the hematol., renal, and hepatobiliary toxicity of imatinib.  Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability.  The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approx. 18 and 40 h, resp.  Approx. 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine.  Cytochrome P 450 3A4 is the main enzyme responsible for imatinib metab.  Phase I and II clin. studies were conducted.  The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day.  Dose-limiting toxicity was not obsd.  The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients.  CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day, imatinib.  Primary study endpoints were cytogenetic response rate (CML-CP) and hematol. response rate (CML-AP and CML-BC).  The cytogenetic response rate for CML-CP patients was 49%.  The hematol. response rate of CML-AP and CML-BC patients was 63 and 26%, resp.  The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea.  Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).  On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufd. and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clin. settings: CML-BC, CML-AP, and CML-CP.  This report summarizes the Food and Drug Administration's review of the New Drug Application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2majxsiqE3LVg90H21EOLACvtfcHk0lj0itsrZtgB5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVSqtbs%253D&md5=8820d9e1126524a6762242f68262ab86</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGobburu%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DK.%26aulast%3DLeighton%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DWood%26aufirst%3DR.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DU%26aufirst%3DK.%2BM.%26aulast%3DStaten%26aufirst%3DA.%2BM.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DApproval%2520summary%2520for%2520imatinib%2520mesylate%2520capsules%2520in%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D935%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kufareva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span> </span><span class="NLM_article-title">Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7921</span><span class="NLM_x">–</span> <span class="NLM_lpage">7932</span><span class="refDoi"> DOI: 10.1021/jm8010299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7921-7932&author=I.+Kufarevaauthor=R.+Abagyan&title=Type-II+kinase+inhibitor+docking%2C+screening%2C+and+profiling+using+modified+structures+of+active+kinase+states&doi=10.1021%2Fjm8010299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span></div><div class="casAuthors">Kufareva, Irina; Abagyan, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7921-7932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type-II kinase inhibitors represent a class of chems. that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site.  These compds. are often more specific than those that target active DFG-in kinase conformations.  Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable.  We present a computational protocol for converting multiple available DFG-in structures of various kinases (∼70% of mammalian structural kinome) into accurate and specific models of their type-II bound state.  The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compd. pose prediction, screening, and in silico activity profiling.  Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific mols. targeting inactive kinase states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp699dzZf5YRLVg90H21EOLACvtfcHk0lic2k_h2osB0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK&md5=64fb7b9f789940dd61c68015341af4a6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm8010299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010299%26sid%3Dliteratum%253Aachs%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DType-II%2520kinase%2520inhibitor%2520docking%252C%2520screening%252C%2520and%2520profiling%2520using%2520modified%2520structures%2520of%2520active%2520kinase%2520states%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7921%26epage%3D7932%26doi%3D10.1021%2Fjm8010299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emkey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span> </span><span class="NLM_article-title">The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">37447</span><span class="NLM_x">–</span> <span class="NLM_lpage">37457</span><span class="refDoi"> DOI: 10.1074/jbc.M112.391425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1074%2Fjbc.M112.391425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22932897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=37447-37457&author=L.+F.+Epsteinauthor=H.+Chenauthor=R.+Emkeyauthor=D.+A.+Whittington&title=The+R1275Q+neuroblastoma+mutant+and+certain+ATP-competitive+inhibitors+stabilize+alternative+activation+loop+conformations+of+anaplastic+lymphoma+kinase&doi=10.1074%2Fjbc.M112.391425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Epstein, Linda F.; Chen, Hao; Emkey, Renee; Whittington, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37447-37457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that, when genetically altered by mutation, amplification, chromosomal translocation or inversion, has been shown to play an oncogenic role in certain cancers.  Small mol. inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.  In neuroblastoma, activating point mutations in the ALK kinase domain can drive disease progression, with the two most common mutations being F1174L and R1275Q.  We report here crystal structures of the ALK kinase domain contg. the F1174L and R1275Q mutations.  Also included are crystal structures of ALK in complex with novel small mol. ALK inhibitors, including a classic type II inhibitor, that stabilize previously unobserved conformations of the ALK activation loop.  Collectively, these structures illustrate a different series of activation loop conformations than has been obsd. in previous ALK crystal structures and provide insight into the activating nature of the R1275Q mutation.  The novel active site topologies presented here may also aid the structure-based drug design of a new generation of ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0rQKncKYwgrVg90H21EOLACvtfcHk0lic2k_h2osB0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqs73K&md5=ac3a068a4837dfb1d63d54826d2b4564</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.391425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.391425%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26atitle%3DThe%2520R1275Q%2520neuroblastoma%2520mutant%2520and%2520certain%2520ATP-competitive%2520inhibitors%2520stabilize%2520alternative%2520activation%2520loop%2520conformations%2520of%2520anaplastic%2520lymphoma%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D37447%26epage%3D37457%26doi%3D10.1074%2Fjbc.M112.391425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W. T.</span><span> </span><span class="NLM_article-title">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2856</span><span class="NLM_x">–</span> <span class="NLM_lpage">2867</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmc.2013.03.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=23618709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2856-2867&author=W.+H.+Linauthor=J.+T.+Hsuauthor=S.+Y.+Hsiehauthor=C.+T.+Chenauthor=J.+S.+Songauthor=S.+C.+Yenauthor=T.+Hsuauthor=C.+T.+Luauthor=C.+H.+Chenauthor=L.+H.+Chouauthor=Y.+N.+Yangauthor=C.+H.+Chiuauthor=C.+P.+Chenauthor=Y.+J.+Tsengauthor=K.+J.+Yenauthor=C.+F.+Yehauthor=Y.+S.+Chaoauthor=T.+K.+Yehauthor=W.+T.+Jiaang&title=Discovery+of+3-phenyl-1H-5-pyrazolylamine+derivatives+containing+a+urea+pharmacophore+as+potent+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmc.2013.03.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Lin, Wen-Hsing; Hsu, John T.-A.; Hsieh, Shu-Yi; Chen, Chiung-Tong; Song, Jen-Shin; Yen, Shih-Chieh; Hsu, Tsu; Lu, Cheng-Tai; Chen, Chun-Hwa; Chou, Ling-Hui; Yang, Yung-Ning; Chiu, Ching-Hui; Chen, Ching-Ping; Tseng, Ya-Ju; Yen, Kuei-Jung; Yeh, Ching-Fang; Chao, Yu-Sheng; Yeh, Teng-Kuang; Jiaang, Weir-Torn</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2856-2867</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preclin. investigations and early clin. trials suggest that FLT3 inhibitors are a viable therapy for acute myeloid leukemia.  However, early clin. data have been underwhelming due to incomplete inhibition of FLT3.  The authors have developed 3-phenyl-1H-5-pyrazolylamine as an efficient template for kinase inhibitors.  Structure-activity relationships led to the discovery of sulfonamide, carbamate and urea series of FLT3 inhibitors.  Previous studies showed that the sulfonamide and carbamate series were potent and selective FLT3 inhibitors with good in vivo efficacy.  Herein, the authors describe the urea series, which the authors found to be potent inhibitors of FLT3 and VEGFR2.  Some inhibited growth of FLT3-mutated MOLM-13 cells more strongly than the FLT3 inhibitors sorafenib and ABT-869.  In preliminary in vivo toxicity studies of the four most active compds., N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide was found to be the least toxic.  A further in vivo efficacy study demonstrated that N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide achieved complete tumor regression in a higher proportion of MOLM-13 xenograft.  These results show that compd. N1-[3-(4-[([5-(tert-Butyl)-3-isoxazolyl]aminocarbonyl)amino]methylphenyl)-1H-5pyrazolyl]-4-(2-morpholinoethoxy)benzamide possesses improved pharmacol. and selectivity profiles and could be more effective than previously disclosed FLT3 inhibitors in the treatment of acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8nbO4pzTXbrVg90H21EOLACvtfcHk0lic2k_h2osB0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVGrsro%253D&md5=3b4f4323360170e8a7fbe763b79d3128</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.083%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BN.%26aulast%3DChiu%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DTseng%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DK.%2BJ.%26aulast%3DYeh%26aufirst%3DC.%2BF.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3DDiscovery%2520of%25203-phenyl-1H-5-pyrazolylamine%2520derivatives%2520containing%2520a%2520urea%2520pharmacophore%2520as%2520potent%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2856%26epage%3D2867%26doi%3D10.1016%2Fj.bmc.2013.03.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W. T.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4173</span><span class="NLM_x">–</span> <span class="NLM_lpage">4182</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmc.2011.06.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=4173-4182&author=W.+H.+Linauthor=S.+Y.+Hsiehauthor=S.+C.+Yenauthor=C.+T.+Chenauthor=T.+K.+Yehauthor=T.+Hsuauthor=C.+T.+Luauthor=C.+P.+Chenauthor=C.+W.+Chenauthor=L.+H.+Chouauthor=Y.+L.+Huangauthor=A.+H.+Chengauthor=Y.+I.+Changauthor=Y.+J.+Tsengauthor=K.+R.+Yenauthor=Y.+S.+Chaoauthor=J.+T.+Hsuauthor=W.+T.+Jiaang&title=Discovery+and+evaluation+of+3-phenyl-1H-5-pyrazolylamine-based+derivatives+as+potent%2C+selective+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmc.2011.06.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DChen%26aufirst%3DC.%2BW.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DA.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BI.%26aulast%3DTseng%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DK.%2BR.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25203-phenyl-1H-5-pyrazolylamine-based%2520derivatives%2520as%2520potent%252C%2520selective%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D4173%26epage%3D4182%26doi%3D10.1016%2Fj.bmc.2011.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hsu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiaang, W. T.</span><span> </span><span class="NLM_article-title">3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4654</span><span class="NLM_x">–</span> <span class="NLM_lpage">4659</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmcl.2012.05.116" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4654-4659&author=J.+T.+Hsuauthor=T.+K.+Yehauthor=S.+C.+Yenauthor=C.+T.+Chenauthor=S.+Y.+Hsiehauthor=T.+Hsuauthor=C.+T.+Luauthor=C.+H.+Chenauthor=L.+H.+Chouauthor=C.+H.+Chiuauthor=Y.+I.+Changauthor=Y.+J.+Tsengauthor=K.+R.+Yenauthor=Y.+S.+Chaoauthor=W.+H.+Linauthor=W.+T.+Jiaang&title=3-Phenyl-1H-5-pyrazolylamine-based+derivatives+as+potent+and+efficacious+inhibitors+of+FMS-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1016%2Fj.bmcl.2012.05.116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.116%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DYen%26aufirst%3DS.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DHsieh%26aufirst%3DS.%2BY.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChou%26aufirst%3DL.%2BH.%26aulast%3DChiu%26aufirst%3DC.%2BH.%26aulast%3DChang%26aufirst%3DY.%2BI.%26aulast%3DTseng%26aufirst%3DY.%2BJ.%26aulast%3DYen%26aufirst%3DK.%2BR.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DJiaang%26aufirst%3DW.%2BT.%26atitle%3D3-Phenyl-1H-5-pyrazolylamine-based%2520derivatives%2520as%2520potent%2520and%2520efficacious%2520inhibitors%2520of%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4654%26epage%3D4659%26doi%3D10.1016%2Fj.bmcl.2012.05.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Tan, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedtke, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavunkel, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perumattam, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nashashibi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liclican, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almirez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugar, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">828</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmcl.2009.12.091" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=828-831&author=X.+F.+Tanauthor=R.+W.+Testerauthor=G.+R.+Luedtkeauthor=S.+Chakravartyauthor=B.+J.+Mavunkelauthor=J.+J.+Perumattamauthor=Q.+Luauthor=I.+Nashashibiauthor=J.+Jungauthor=J.+Huauthor=A.+Liclicanauthor=R.+Almirezauthor=J.+Taboraauthor=V.+Tranauthor=M.+Laneyauthor=D.+E.+Levyauthor=S.+Dugar&title=Design+and+synthesis+of+piperazine-indole+p38+alpha+MAP+kinase+inhibitors+with+improved+pharmacokinetic+profiles&doi=10.1016%2Fj.bmcl.2009.12.091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.091%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DX.%2BF.%26aulast%3DTester%26aufirst%3DR.%2BW.%26aulast%3DLuedtke%26aufirst%3DG.%2BR.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DMavunkel%26aufirst%3DB.%2BJ.%26aulast%3DPerumattam%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DNashashibi%26aufirst%3DI.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DAlmirez%26aufirst%3DR.%26aulast%3DTabora%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DV.%26aulast%3DLaney%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDugar%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520piperazine-indole%2520p38%2520alpha%2520MAP%2520kinase%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520profiles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D828%26epage%3D831%26doi%3D10.1016%2Fj.bmcl.2009.12.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span>MarvinSketch <a href="https://www.chemaxon.com/products/marvin/marvinsketch/" class="extLink">https://www.chemaxon.com/products/marvin/marvinsketch/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=MarvinSketch+https%3A%2F%2Fwww.chemaxon.com%2Fproducts%2Fmarvin%2Fmarvinsketch%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Donella-Deana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunby, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrarese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tartari, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, L. A.</span><span> </span><span class="NLM_article-title">Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">8533</span><span class="NLM_x">–</span> <span class="NLM_lpage">8542</span><span class="refDoi"> DOI: 10.1021/bi0472954</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0472954" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=8533-8542&author=A.+Donella-Deanaauthor=O.+Marinauthor=L.+Cesaroauthor=R.+H.+Gunbyauthor=A.+Ferrareseauthor=A.+M.+Colucciaauthor=C.+J.+Tartariauthor=L.+Mologniauthor=L.+Scapozzaauthor=C.+Gambacorti-Passeriniauthor=L.+A.+Pinna&title=Unique+substrate+specificity+of+anaplastic+lymphoma+kinase+%28ALK%29%3A+development+of+phosphoacceptor+peptides+for+the+assay+of+ALK+activity&doi=10.1021%2Fbi0472954"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi0472954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0472954%26sid%3Dliteratum%253Aachs%26aulast%3DDonella-Deana%26aufirst%3DA.%26aulast%3DMarin%26aufirst%3DO.%26aulast%3DCesaro%26aufirst%3DL.%26aulast%3DGunby%26aufirst%3DR.%2BH.%26aulast%3DFerrarese%26aufirst%3DA.%26aulast%3DColuccia%26aufirst%3DA.%2BM.%26aulast%3DTartari%26aufirst%3DC.%2BJ.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DUnique%2520substrate%2520specificity%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%253A%2520development%2520of%2520phosphoacceptor%2520peptides%2520for%2520the%2520assay%2520of%2520ALK%2520activity%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D8533%26epage%3D8542%26doi%3D10.1021%2Fbi0472954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haste, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17783</span><span class="NLM_x">–</span> <span class="NLM_lpage">17788</span><span class="refDoi"> DOI: 10.1073/pnas.0607656103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1073%2Fpnas.0607656103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=17095602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17783-17788&author=A.+P.+Kornevauthor=N.+M.+Hasteauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=Surface+comparison+of+active+and+inactive+protein+kinases+identifies+a+conserved+activation+mechanism&doi=10.1073%2Fpnas.0607656103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span></div><div class="casAuthors">Kornev, Alexandr P.; Haste, Nina M.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17783-17788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The surface comparison of different serine-threonine and tyrosine kinases reveals a set of 30 residues whose spatial positions are highly conserved.  The comparison between active and inactive conformations identified the residues whose positions are the most sensitive to activation.  Based on these results, we propose a model of protein kinase activation.  This model explains how the presence of a phosphate group in the activation loop dets. the position of the catalytically important aspartate in the Asp-Phe-Gly (DFG) motif.  According to the model, the most important feature of the activation is a "spine" formation that is dynamically assembled in all active kinases.  The spine is comprised of four hydrophobic residues that we detected in a set of 23 eukaryotic and prokaryotic kinases.  It spans the mol. and plays a coordinating role in activated kinases.  The spine is disordered in the inactive kinases and can explain how stabilization of the whole mol. is achieved upon phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwv4ByA5owH7Vg90H21EOLACvtfcHk0lhcdru5nZDLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ&md5=f474acffd8b17d8352ac9f6fc9bbbf8f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607656103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607656103%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHaste%26aufirst%3DN.%2BM.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DSurface%2520comparison%2520of%2520active%2520and%2520inactive%2520protein%2520kinases%2520identifies%2520a%2520conserved%2520activation%2520mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D17783%26epage%3D17788%26doi%3D10.1073%2Fpnas.0607656103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Jura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endres, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.molcel.2011.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.molcel.2011.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=21474065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=9-22&author=N.+Juraauthor=X.+Zhangauthor=N.+F.+Endresauthor=M.+A.+Seeligerauthor=T.+Schindlerauthor=J.+Kuriyan&title=Catalytic+control+in+the+EGF+receptor+and+its+connection+to+general+kinase+regulatory+mechanisms&doi=10.1016%2Fj.molcel.2011.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms</span></div><div class="casAuthors">Jura, Natalia; Zhang, Xue-Wu; Endres, Nicholas F.; Seeliger, Markus A.; Schindler, Thomas; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  In contrast to the active conformations of protein kinases, which are essentially the same for all kinases, inactive kinase conformations are structurally diverse.  Some inactive conformations are, however, obsd. repeatedly in different kinases, perhaps reflecting an important role in catalysis.  In this review, we analyze one of these recurring conformations, first identified in CDK and Src kinases, which turned out to be central to understanding of how kinase domain of the EGF receptor is activated.  This mechanism, which involves the stabilization of the active conformation of an α helix, has features in common with mechanisms operative in several other kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzfvk5EtYFJLVg90H21EOLACvtfcHk0lhcdru5nZDLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqt74%253D&md5=b891148117e35a5428fafee3a9efe06d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2011.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2011.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DJura%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DEndres%26aufirst%3DN.%2BF.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCatalytic%2520control%2520in%2520the%2520EGF%2520receptor%2520and%2520its%2520connection%2520to%2520general%2520kinase%2520regulatory%2520mechanisms%26jtitle%3DMol.%2520Cell%26date%3D2011%26volume%3D42%26spage%3D9%26epage%3D22%26doi%3D10.1016%2Fj.molcel.2011.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Protein kinases: evolution of dynamic regulatory proteins</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1016/j.tibs.2010.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.tibs.2010.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=20971646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=65-77&author=S.+S.+Taylorauthor=A.+P.+Kornev&title=Protein+kinases%3A+evolution+of+dynamic+regulatory+proteins&doi=10.1016%2Fj.tibs.2010.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases: evolution of dynamic regulatory proteins</span></div><div class="casAuthors">Taylor, Susan S.; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases have evolved as a family of highly dynamic mols. with a strictly organized internal architecture.  A single hydrophobic F-helix serves as a central scaffold for the assembly of the entire mol.  Two non-consecutive hydrophobic structures termed "spines" anchor all of the elements important for catalysis to the F-helix.  They make firm, but flexible, connections within the mol., providing a high level of internal dynamics of the protein kinase.  During the course of evolution, protein kinases developed a universal regulatory mechanism assocd. with a large activation segment that can be dynamically folded and unfolded in the course of cell functioning.  Protein kinases thus represent a unique, highly dynamic, and precisely regulated set of switches that control most biol. events in eukaryotic cells.  A comparison of 155 publicly available protein kinase structures of the human kinome, which includes 518 protein kinases divided into 7 major subfamilies, demonstrates a high level of structural plasticity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruzcRXGPlBN7Vg90H21EOLACvtfcHk0li5TjmH5p1oHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOrtLg%253D&md5=f663148962d22944914e804e34fc947c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DProtein%2520kinases%253A%2520evolution%2520of%2520dynamic%2520regulatory%2520proteins%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2011%26volume%3D36%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.tibs.2010.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Palmer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernersson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, B.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: signalling in development and disease</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">420</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1042/BJ20090387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1042%2FBJ20090387" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2009&pages=345-361&author=R.+H.+Palmerauthor=E.+Vernerssonauthor=C.+Grabbeauthor=B.+Hallberg&title=Anaplastic+lymphoma+kinase%3A+signalling+in+development+and+disease&doi=10.1042%2FBJ20090387"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1042%2FBJ20090387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20090387%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BH.%26aulast%3DVernersson%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DC.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520signalling%2520in%2520development%2520and%2520disease%26jtitle%3DBiochem.%2520J.%26date%3D2009%26volume%3D420%26spage%3D345%26epage%3D361%26doi%3D10.1042%2FBJ20090387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L. C.</span><span> </span><span class="NLM_article-title">Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1074/jbc.M109.059758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1074%2Fjbc.M109.059758" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=95-103&author=P.+Wangauthor=F.+Wuauthor=Y.+Maauthor=L.+Liauthor=R.+Laiauthor=L.+C.+Young&title=Functional+characterization+of+the+kinase+activation+loop+in+nucleophosmin+%28NPM%29-anaplastic+lymphoma+kinase+%28ALK%29+using+tandem+affinity+purification+and+liquid+chromatography-mass+spectrometry&doi=10.1074%2Fjbc.M109.059758"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.059758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.059758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DL.%2BC.%26atitle%3DFunctional%2520characterization%2520of%2520the%2520kinase%2520activation%2520loop%2520in%2520nucleophosmin%2520%2528NPM%2529-anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520using%2520tandem%2520affinity%2520purification%2520and%2520liquid%2520chromatography-mass%2520spectrometry%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D95%26epage%3D103%26doi%3D10.1074%2Fjbc.M109.059758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Zorn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barros, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0121177</span><span class="refDoi"> DOI: 10.1371/journal.pone.0121177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1371%2Fjournal.pone.0121177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=25837374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0121177&author=J.+A.+Zornauthor=Q.+Wangauthor=E.+Fujimuraauthor=T.+Barrosauthor=J.+Kuriyan&title=Crystal+structure+of+the+FLT3+kinase+domain+bound+to+the+inhibitor+Quizartinib+%28AC220%29&doi=10.1371%2Fjournal.pone.0121177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)</span></div><div class="casAuthors">Zorn, Julie A.; Wang, Qi; Fujimura, Eric; Barros, Tiago; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0121177/1-e0121177/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3.  A small-mol. inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clin. trials appears promising for the treatment of AML.  Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib.  FLT3 with quizartinib bound adopts an "Abl-like"inactive conformation with the activation loop stabilized in the "DFG-out"orientation and folded back onto the kinase domain.  This conformation is similar to that obsd. for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop.  The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant obsd. in many AML patients.  This co-complex further provides a structural rationale for quizartinib-resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXAklBbZKP7Vg90H21EOLACvtfcHk0li5TjmH5p1oHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Gmsr%252FM&md5=d3c23bf8a8e242dd35e20e6e9b2de924</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0121177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0121177%26sid%3Dliteratum%253Aachs%26aulast%3DZorn%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFujimura%26aufirst%3DE.%26aulast%3DBarros%26aufirst%3DT.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520FLT3%2520kinase%2520domain%2520bound%2520to%2520the%2520inhibitor%2520Quizartinib%2520%2528AC220%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0121177%26doi%3D10.1371%2Fjournal.pone.0121177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">31655</span><span class="NLM_x">–</span> <span class="NLM_lpage">31663</span><span class="refDoi"> DOI: 10.1074/jbc.M403319200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.+C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+STI-571+inhibition+of+c-Kit+tyrosine+kinase&doi=10.1074%2Fjbc.M403319200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Å resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Å crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0ljiNaRR02cRGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520STI-571%2520inhibition%2520of%2520c-Kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D31655%26epage%3D31663%26doi%3D10.1074%2Fjbc.M403319200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">18281</span><span class="NLM_x">–</span> <span class="NLM_lpage">18289</span><span class="refDoi"> DOI: 10.1073/pnas.1207759109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.+L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+conformations%2C+interactions%2C+and+properties+associated+with+drug+efficiency+and+clinical+performance+among+VEGFR+TK+inhibitors&doi=10.1073%2Fpnas.1207759109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0ljiNaRR02cRGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520conformations%252C%2520interactions%252C%2520and%2520properties%2520associated%2520with%2520drug%2520efficiency%2520and%2520clinical%2520performance%2520among%2520VEGFR%2520TK%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289%26doi%3D10.1073%2Fpnas.1207759109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6652</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0ljiNaRR02cRGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Chaikuad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacconi, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsounas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/nchembio.1629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1038%2Fnchembio.1629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=25195011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=853-860&author=A.+Chaikuadauthor=E.+M.+Tacconiauthor=J.+Zimmerauthor=Y.+Liangauthor=N.+S.+Grayauthor=M.+Tarsounasauthor=S.+Knapp&title=A+unique+inhibitor+binding+site+in+ERK1%2F2+is+associated+with+slow+binding+kinetics&doi=10.1038%2Fnchembio.1629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics</span></div><div class="casAuthors">Chaikuad, Apirat; M C Tacconi, Eliana; Zimmer, Jutta; Liang, Yanke; Gray, Nathanael S.; Tarsounas, Madalena; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">853-860</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs.  Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor.  Here we report the structural mechanism for its remarkable selectivity.  In ERK1/2, SCH772984 induces a so-far-unknown binding pocket that accommodates the piperazine-phenyl-pyrimidine decoration.  This new binding pocket was created by an inactive conformation of the phosphate-binding loop and an outward tilt of helix αC.  In contrast, structure detn. of SCH772984 with the off-target haspin and JNK1 revealed two canonical but distinct type I binding modes.  Notably, the new binding mode with ERK1/2 was assocd. with slow binding kinetics in vitro as well as in cell-based assay systems.  The described binding mode of SCH772984 with ERK1/2 enables the design of a new type of specific kinase inhibitors with prolonged on-target activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdNjmmeHD_-LVg90H21EOLACvtfcHk0lgsKmbyb6ke-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKms7vN&md5=b54251bd7486f0df266d8423ae9c627d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1629%26sid%3Dliteratum%253Aachs%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DTacconi%26aufirst%3DE.%2BM.%26aulast%3DZimmer%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DTarsounas%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DA%2520unique%2520inhibitor%2520binding%2520site%2520in%2520ERK1%252F2%2520is%2520associated%2520with%2520slow%2520binding%2520kinetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D853%26epage%3D860%26doi%3D10.1038%2Fnchembio.1629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallwood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koretke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calamari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span> </span><span class="NLM_article-title">Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1791</span><span class="NLM_x">–</span> <span class="NLM_lpage">1797</span><span class="refDoi"> DOI: 10.1110/ps.036590.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1110%2Fps.036590.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=18662907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cit7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1791-1797&author=B.+Zhaoauthor=A.+Smallwoodauthor=J.+Yangauthor=K.+Koretkeauthor=K.+Nurseauthor=A.+Calamariauthor=R.+B.+Kirkpatrickauthor=Z.+Lai&title=Modulation+of+kinase-inhibitor+interactions+by+auxiliary+protein+binding%3A+crystallography+studies+on+Aurora+A+interactions+with+VX-680+and+with+TPX2&doi=10.1110%2Fps.036590.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2</span></div><div class="casAuthors">Zhao, Baoguang; Smallwood, Angela; Yang, Jingsong; Koretke, Kristin; Nurse, Kelvin; Calamari, Amy; Kirkpatrick, Robert B.; Lai, Zhihong</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1791-1797</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">VX-680, also known as MK-0457, is an ATP-competitive small mol. inhibitor of the Aurora kinases that has entered phase II clin. trials for the treatment of cancer.  We have solved the cocrystal structure of AurA/TPX2/VX-680 at 2.3 Å resoln.  In the crystal structure, VX-680 binds to the active conformation of AurA.  The glycine-rich loop in AurA adopts a unique bent conformation, forming a π-π interaction with the Ph group of VX-680.  In contrast, in the published AurA/VX-680 structure, VX-680 binds to AurA in the inactive conformation, interacting with a hydrophobic pocket only present in the inactive conformation.  These data suggest that TPX2, a protein cofactor, can alter the binding mode of VX-680 with AurA.  More generally, the presence of physiol. relevant cofactor proteins can alter the kinetics, binding interactions, and inhibition of enzymes, and studies with these multiprotein complexes may be beneficial to the discovery and optimization of enzyme inhibitors as therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7jnb6hGH-SbVg90H21EOLACvtfcHk0lgsKmbyb6ke-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cit7rM&md5=622cf5907d6af38a1bc53481fd0b35d4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1110%2Fps.036590.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.036590.108%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKoretke%26aufirst%3DK.%26aulast%3DNurse%26aufirst%3DK.%26aulast%3DCalamari%26aufirst%3DA.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DLai%26aufirst%3DZ.%26atitle%3DModulation%2520of%2520kinase-inhibitor%2520interactions%2520by%2520auxiliary%2520protein%2520binding%253A%2520crystallography%2520studies%2520on%2520Aurora%2520A%2520interactions%2520with%2520VX-680%2520and%2520with%2520TPX2%26jtitle%3DProtein%2520Sci.%26date%3D2008%26volume%3D17%26spage%3D1791%26epage%3D1797%26doi%3D10.1110%2Fps.036590.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">4236</span><span class="NLM_x">–</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lgDmSnSs_jBmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peet, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">The kinetics of binding to p38MAP kinase by analogues of BIRB 796</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3101</span><span class="NLM_x">–</span> <span class="NLM_lpage">3104</span><span class="refDoi"> DOI: 10.1016/S0960-894X(03)00656-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS0960-894X%2803%2900656-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=12941343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1Gmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=3101-3104&author=J.+Reganauthor=C.+A.+Pargellisauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=E.+R.+Hickeyauthor=G.+W.+Peetauthor=A.+Protoauthor=A.+Swinamerauthor=N.+Moss&title=The+kinetics+of+binding+to+p38MAP+kinase+by+analogues+of+BIRB+796&doi=10.1016%2FS0960-894X%2803%2900656-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of binding to p38 MAP kinase of analogues of BIRB 796</span></div><div class="casAuthors">Regan, John; Pargellis, Christopher A.; Cirillo, Pier F.; Gilmore, Thomas; Hickey, Eugene R.; Peet, Gregory W.; Proto, Alfred; Swinamer, Alan; Moss, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3101-3104</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">BIRB 796, a member of the N-pyrazole-N'-naphthyl urea class of p38 MAPK inhibitors, binds to the kinase with both slow assocn. and dissocn. rates.  Prior to binding, the kinase undergoes a reorganization of the activation loop exposing a crit. binding domain.  We demonstrate that, independent of the loop movement, assocn. rates are governed by low energy conformations of the inhibitor and polar functionality on the tolyl ring.  As anticipated, the dissocn. rates of the inhibitors from the kinase are slowed by lipophilic and hydrogen bond interactions.  The value of structure-kinetic relationships (SKR) in drug design is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr1jPKElIlvrVg90H21EOLACvtfcHk0lgDmSnSs_jBmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1Gmt7s%253D&md5=1ca2cb661cf037790ec1b0b43a105cf3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900656-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900656-5%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DPeet%26aufirst%3DG.%2BW.%26aulast%3DProto%26aufirst%3DA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DThe%2520kinetics%2520of%2520binding%2520to%2520p38MAP%2520kinase%2520by%2520analogues%2520of%2520BIRB%2520796%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D3101%26epage%3D3104%26doi%3D10.1016%2FS0960-894X%2803%2900656-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lgDmSnSs_jBmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkoczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lgDmSnSs_jBmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lgZpIOll274-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Shultz, M. D.</span><span> </span><span class="NLM_article-title">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5980</span><span class="NLM_x">–</span> <span class="NLM_lpage">5991</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=10.1016%2Fj.bmcl.2013.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=24018190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+expectations+in+molecular+optimizations%3A+Strengths+and+limitations+of+commonly+used+composite+parameters&doi=10.1016%2Fj.bmcl.2013.08.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5980-5991</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the past 15 years there have been extensive efforts to understand and reduce the high attrition rates of drug candidates with an increased focus on physicochem. properties.  The fruits of this labor have been the generation of numerous efficiency indexes, metric-based rules and visualization tools to help guide medicinal chemists in the design of new compds. with more favorable properties.  This deluge of information may have had the unintended consequence of further obfuscating mol. optimizations by the inability of these scoring functions, rules and guides to reach a consensus on when a particular transformation is identified as beneficial.  In this manuscript, several composite parameters, or efficiency indexes, are examd. utilizing theor. and exptl. matched mol. pair analyses in order to understand the basis for how each will perform under varying scenarios of mol. optimizations.  In contrast to empirically derived composite parameters based on heavy atom count, lipophilic efficiency (LipE) sets consistent expectations regardless of mol. wt. or relative potency and can be used to generate consistent expectations for any matched mol. pair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJeTISXSJyLbVg90H21EOLACvtfcHk0lgZpIOll274-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI&md5=3b766e26254f482b75b8973888c13aec</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520expectations%2520in%2520molecular%2520optimizations%253A%2520Strengths%2520and%2520limitations%2520of%2520commonly%2520used%2520composite%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991%26doi%3D10.1016%2Fj.bmcl.2013.08.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XUF','PDB','4XUF'); return false;">PDB: 4XUF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46','PDB','1T46'); return false;">PDB: 1T46</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD','PDB','4ASD'); return false;">PDB: 4ASD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E5A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E5A','PDB','3E5A'); return false;">PDB: 3E5A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP','PDB','1IEP'); return false;">PDB: 1IEP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2','PDB','1KV2'); return false;">PDB: 1KV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2','PDB','2XP2'); return false;">PDB: 2XP2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FNY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4FNY','PDB','4FNY'); return false;">PDB: 4FNY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUG','PDB','5IUG'); return false;">PDB: 5IUG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUH','PDB','5IUH'); return false;">PDB: 5IUH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUI','PDB','5IUI'); return false;">PDB: 5IUI</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00106">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47666"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00106">10.1021/acs.jmedchem.6b00106</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Binding kinetics analysis of <b>5a</b>, <b>4</b>, and crizotinib; density maps of <b>5a</b>, <b>4</b>, and <b>5d</b> in the active site of ALK; docking position of the designed ALK inhibitor in the binding site of ALK (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_001.pdf">jm6b00106_si_001.pdf (891.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00106/suppl_file/jm6b00106_si_002.csv">jm6b00106_si_002.csv (1.15 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are the following: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUG">5IUG</a> (ALK/<b>5a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUH">5IUH</a> (ALK/<b>5d</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IUI">5IUI</a> (ALK/<b>4</b>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00106&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00106%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-8%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00106" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f253da613db8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
